<PAGE>
================================================================================
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K/A-2
----------------------------
(Mark One)
[X] Annual report pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934
For the fiscal year ended December 31, 1998
OR
[ ] Transition report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Commission file number 0-26190
AMERICAN ONCOLOGY RESOURCES, INC.
(Exact name of registrant as specified in its charter)
Delaware 84-1213501
(STATE OR OTHER JURISDICTION OF (I.R.S. EMPLOYER IDENTIFICATION NO.)
INCORPORATION OR ORGANIZATION)
16825 Northchase Drive, Suite 1300, Houston, Texas 77060
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE)
Registrant's telephone number, including area code: (281) 873-2674
Securities registered pursuant to Section 12(b) of the Act:
None
Securities registered pursuant to Section 12(g) of the Act:
Common Stock ($.01 par value)
(Title of class)
Series A Preferred Stock Purchase Rights
(Title of class)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes X No
----- -----
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulations S-K is not contained herein, and will not be contained, to the
best of Registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K. X
-----
The aggregate market value of the voting stock held by non-affiliates of the
Registrant as of March 12, 1999 was $239,338,034 (based upon the closing sales
price of the Common Stock on The Nasdaq Stock Market on March 12, 1999 of $8.63
per share). For purposes of this calculation, shares held by non-affiliates
exclude only those shares beneficially owned by officers, directors and
stockholders beneficially owning 10% or more of the outstanding Common Stock.
There were 33,449,681 shares of the Registrant's Common Stock outstanding on
March 12, 1999. In addition, as of March 12, 1999, the Registrant had agreed to
deliver 15,807,578 shares of its Common Stock on certain future dates for no
additional consideration.
DOCUMENTS INCORPORATED BY REFERENCE
None
================================================================================
<PAGE>
PART I
ITEM 1. BUSINESS
American Oncology Resources, Inc. (together with its subsidiaries, "AOR" or
the "Company") is a cancer management company. As of March 12, 1999, the
Company provided comprehensive management services under long-term agreements to
oncology practices comprised of 380 physicians in 18 states. The physicians
affiliated with AOR provide all aspects of care related to the diagnosis and
outpatient treatment of cancer, including medical oncology, radiation oncology,
gynecological oncology, stem cell transplantation, diagnostic radiology and
clinical research. The Company was incorporated in October 1992 under the laws
of the State of Delaware. The Company's principal executive offices are located
at 16825 Northchase Drive, Suite 1300, Houston, Texas, and its telephone number
is (281) 873-2674.
Effective December 11, 1998, the Company entered into a definitive
agreement to merge with Physician Reliance Network, Inc. ("PRN"). As of March
12, 1999, PRN provided comprehensive management services under long-term
agreements to medical practices comprised of 367 physicians in twelve states.
Under the terms of the merger agreement, holders of PRN common stock will
receive a fixed ratio of 0.94 shares of the Company's common stock for each PRN
share held. As a result, stockholders of the Company and PRN will each own
approximately 50% of the combined company on a fully diluted basis. Following
the merger, PRN will be a wholly owned subsidiary of the Company. The
transaction is expected to be accounted for under the pooling of interests
method of accounting and treated as a tax-free exchange. Closing of the
transaction is anticipated in the second quarter of 1999, subject to stockholder
approval of both companies, regulatory approval and other customary conditions.
After consummation of the transaction, the Company's financial statements will
be retroactively restated to combine the accounts of the Company and PRN for all
periods presented using their historical basis.
Management Services
The Company is a cancer management company, and its primary business is
providing comprehensive management services to oncology practices, including the
following:
STRATEGIC SERVICES. At each affiliated practice, a policy board comprised
of equal representation from the Company and affiliated physicians is created to
develop and adopt a strategic plan designed to improve the performance of the
practice by (i) outlining physician recruiting goals, (ii) identifying services
and equipment to be added, (iii) identifying desirable payor relationships and
other oncology groups that are possible affiliation candidates and (iv)
facilitating communication with other affiliated physician groups in the AOR
network.
FINANCIAL SERVICES. The Company provides comprehensive financial analysis
to each affiliated physician group in connection with managed care contracting
and billing, collection, reimbursement, tax and accounting services. The
Company also implements its cash management system. In addition, the Company
and the affiliated physician group jointly develop a comprehensive budget that
involves the adoption of financial controls and cost containment measures.
MANAGEMENT INFORMATION SYSTEMS. The Company implements its management
information system to facilitate and organize the exchange of clinical and
operational information among the Company's affiliated physicians. The Company
believes that an integrated information system will enable the Company and its
affiliated physicians to identify effective protocols and manage the costs of
cancer care in future years. The Company intends to significantly expand its
clinical information system in 1999, with the goal of providing its affiliated
physicians with the tools to provide high quality, cost effective cancer care.
ADMINISTRATIVE SERVICES. The Company manages the facilities used by the
affiliated physicians and, in coordination with the physicians, determines the
number and location of practice sites. The Company provides support for
practice management, billing functions and patient record keeping. The Company
also provides comprehensive purchasing services for drugs, supplies, equipment,
insurance and other practice requirements. In addition, the Company provides
regulatory expertise to assist the group in complying with increasingly complex
laws and regulations applicable to oncology practices.
PERSONNEL MANAGEMENT. The Company employs and manages all nonmedical
personnel of the physician group, including the executive director, controller
and other administrative personnel. The Company evaluates these employees,
makes staffing recommendations, provides and manages employee benefits and
implements personnel policies and procedures. The Company also provides similar
administrative services to the physician group's employees.
<PAGE>
CLINICAL RESEARCH SERVICES. Through its clinical research network, the
Company facilitates and organizes clinical research conducted by its affiliated
physician groups and markets the groups' ability to perform and manage clinical
trials to pharmaceutical and biotechnology companies. Clinical research
conducted by the oncology groups focuses on (i) improving cancer survival rates,
(ii) enhancing the cancer patient's quality of life, (iii) reducing the costs of
cancer care and (iv) developing new approaches to cancer diagnosis, treatment
and post-treatment monitoring. The Company assists in a number of aspects in
the conduct of clinical trials, including protocol development, data
coordination, institutional review board coordination and contract review and
negotiation.
CLINICAL INITIATIVES AND STANDARDS. The Company organizes clinical
conferences for its affiliated physicians to discuss and identify clinical care,
research and educational strategies for the Company's network of affiliated
physicians. The Company also assists its affiliated physicians in developing
clinical practice guidelines for the different types of cancer and in operating
in accordance with standards of care required for accreditation by managed care
accreditation bodies. The Company is also implementing a clinical information
system with the goal of facilitating the exchange of information among
affiliated physicians. The Company expects the system will enable the
physicians to share clinical data and treatment patterns and will allow ready
access to current protocols and information regarding cancer therapies and
research developments.
Operations of Oncology Groups
Since the Company's incorporation in October 1992, the Company has grown
rapidly from managing a single practice comprised of six physicians in one state
to managing oncology practices comprised of 380 physicians in 18 states as of
March 12, 1999.
The Company estimates that most of the affiliated physician groups are
among the largest group practices providing cancer care in their markets. The
physician members of these groups have staff privileges at most private
hospitals in their markets and have long-standing relationships with
governmental and private payors.
The oncologists are employed by the affiliated physician groups, not the
Company, and maintain control over all aspects of the provision of medical care
to their patients. The Company does not provide medical care to patients or
employ any of the non-physician personnel of its affiliated physician groups who
provide medical care. However, under the terms of the management agreements
with the affiliated physician groups, the Company is responsible for the
compensation and benefits of the groups' non-physician medical personnel, and
the financial statements of the Company reflect the costs of such compensation
and benefits.
The affiliated physician groups offer a wide array of services to cancer
patients in outpatient settings, including professional medical services,
chemotherapy infusion and radiation oncology services, stem cell
transplantation, clinical laboratory, diagnostic radiology, pharmacy services
and patient education. The groups employ a range of personnel to provide these
services, such as medical assistants, nurses (including oncology certified
nurses), radiation therapy technicians, physicists and laboratory and pharmacy
technicians. The practice sites are generally located in close proximity to
other health care providers and typically are equipped to provide the outpatient
services necessary to treat and care for cancer patients and their families.
Affiliation Structure
The Company's structure enables its affiliated physicians to retain their
autonomy through ownership and participation in their local professional
corporation or other entity, thereby maintaining local authority and control
over medical practice decisions. The Company believes that this local
governance structure is critical to its success.
Identifying appropriate physician groups and proposing, negotiating and
implementing economically attractive affiliations with them is a lengthy,
complex and costly process, typically requiring three to six months. In
connection with affiliating with an oncology group, the Company enters into a
management agreement with the group and purchases the group's nonmedical assets.
In consideration of these arrangements, the Company typically pays cash and
promissory notes and agrees to deliver shares of its Common Stock at specified
future dates (typically on the third through fifth anniversaries of the closing
date). The Company's obligation to deliver its shares is unconditional and is
not contingent on any physician remaining employed by a physician group or the
physician group's continued affiliation with the Company. In addition, each
affiliated physician enters into an employment agreement with the physician
group. The Company believes that the delivery of shares on a delayed basis, the
Company's affiliation structure and the compensation formulas defined in the
management agreements all serve to align the long-term interests of the
affiliated physicians with those of the Company.
2
<PAGE>
All of the management service agreements with the affiliated physician
groups have contractual terms of 40 years. These agreements cannot be
terminated by the physician groups without cause. As consideration for the
Company's management services, each management agreement provides for payment to
the Company of a management fee, which typically includes all practice costs
(other than amounts retained by physicians), a fixed fee, a percentage fee (in
most states) and, if certain financial and performance criteria are satisfied, a
performance fee.
The amount of the fixed fee is related to the size of the affiliated
physician group and the consideration delivered in connection with the
affiliation transaction and, as a result, varies significantly among the
management service agreements. The percentage fee, where permitted by
applicable law, is generally seven percent of the affiliated physician group's
net revenue. Performance fees are paid after payment of all practice expenses,
physician compensation and the other management fees and, where permitted by
state law, are approximately 50% of the residual profitability of the physician
group. Management fees are not subject to adjustment, with the exception that
the fixed fee may be adjusted from time to time after the fifth year of the
management agreement to reflect inflationary trends. The management service
agreements permit the affiliated physician group to retain a specified amount
(typically 23% of the group's net revenues) for physician salaries, and payment
of such salaries is given priority over payment of the management fee. The
affiliated physician group is also entitled to retain all profits of the
practice after payment of the management fee to the Company. As a result of this
arrangement, the Company benefits from increases in the affiliated group's net
revenue but maintains the incentive to control its expenses.
The employment agreements between the physician group and its affiliated
physicians have initial terms of five years in the case of physicians who are
shareholders of the group and one year in the case of non-shareholder
physicians, and both types of agreements provide for successive one year renewal
periods. Each employment agreement also includes provisions setting forth the
circumstances under which the agreement may be terminated for cause and a non-
competition provision that applies for one year following termination of the
physician's employment. In addition, each employment agreement provides for the
payment of specified liquidated damages to the physician group, not to the
Company, in the event the physician terminates the agreement without cause or
breaches the non-competition provision.
Competition
The business of providing health care services generally, and of managing
and providing oncology services specifically, is intensely competitive. The
Company is aware of several competitors specializing in the management of
oncology practices. In addition, several health care companies with established
operating histories and significantly greater resources than the Company are
also providing at least some management services to oncologists. Furthermore,
the Company believes that others in the health care industry may adopt
strategies similar to those of the Company. The Company's revenues depend on
the continued success of its affiliated physician groups. These physician
groups face competition from several sources, including sole practitioners,
single and multi-specialty groups, hospitals and managed care organizations.
Regulation
General. The health care industry is highly regulated, and there can be no
assurance that the regulatory environment in which the Company and its
affiliated physician groups operate will not change significantly and adversely
in the future. In general, regulation and scrutiny of health care providers and
companies are increasing.
There are currently several federal and state initiatives to amend
regulations relating to the provision of health care services, access to health
care, disclosure of health care information, costs of health care and the manner
in which health care providers are reimbursed for their services. It is not
possible to predict whether any such initiatives will be enacted as legislation
or, if enacted, what their form, effective dates or impact on the Company will
be.
The Company's affiliated physician groups are intensely regulated at the
federal, state and local levels. Although these regulations often do not
directly apply to the Company, to the extent an affiliated physician group is
found to have violated any of these regulations and, as a result, suffers a
decrease in its revenues or an increase in costs, the Company's results of
operations might be materially and adversely affected.
Every state imposes licensing requirements on individual physicians and on
facilities and services operated or provided by physicians. Many states require
regulatory approval, including certificates of need, before (a) establishing
certain types of health care facilities, (b) offering certain services or (c)
expending monies in excess of statutory thresholds for health care equipment,
facilities or programs. The execution of a management agreement with a
physician group currently does not require any regulatory approval on the part
of the Company or the physician group. However, in connection with the
3
<PAGE>
expansion of existing operations and the entry into new markets, the Company and
its affiliated physician groups may become subject to additional regulation.
Fee-Splitting; Corporate Practice of Medicine. The laws of many states
prohibit physicians from splitting professional fees with non-physicians and
prohibit non-physician entities, such as the Company, from practicing medicine
and from employing physicians to practice medicine. The laws in most states
regarding the corporate practice of medicine have been subjected to relatively
limited judicial and regulatory interpretation. The Company believes its
current and planned activities do not constitute fee-splitting or the practice
of medicine as contemplated by these statutes and interpretations. However,
there can be no assurance that future interpretations of such laws will not
require structural and organizational modification of the Company's existing
relationships with the affiliated physician groups. In addition, statutes in
some states in which the Company does not currently operate could require the
Company to modify its affiliation structure.
Medicare/Medicaid Fraud and Abuse Provisions. Federal law prohibits the
offer, payment, solicitation or receipt of any form of remuneration in return
for the referral of Medicare or state health program patients or patient care
opportunities, or in return for the purchase, lease or order of any item or
service that is covered by Medicare or a state health program. Pursuant to this
law, the federal government has pursued a policy of increased scrutiny of joint
ventures and other transactions among health care providers in an effort to
reduce potential fraud and abuse relating to government health care costs. The
applicability of these provisions to many business practices in the health care
industry, including the Company's arrangements with its affiliated physician
groups, has not been subject to judicial and regulatory interpretation.
The Medicare and Medicaid anti-kickback amendments (the "Anti-Kickback
Amendments") provide criminal penalties for individuals or entities
participating in the Medicare or Medicaid programs who knowingly and willfully
offer, pay, solicit or receive remuneration in order to induce referrals for
items or services reimbursed under such programs. In addition to federal
criminal penalties, the Social Security Act also includes the intermediate
sanction of excluding violators from participation in the Medicare or Medicaid
programs.
A violation of the Anti-Kickback Amendments requires several elements: (i)
the offer, payment, solicitation or receipt of remuneration; (ii) the intent to
induce referrals; (iii) the ability of the parties to make or influence
referrals of patients; (iv) the provision of services that are reimbursable
under Medicare or state health programs; and (v) patient coverage under the
Medicare program or a state health program. The Company believes that it is
receiving compensation under the management agreements for management services.
The Company also believes that it is not in a position to make or influence
referrals of patients or services reimbursed under Medicare or state health
programs to its affiliated physician groups. Consequently, the Company does not
believe that the management fees payable to it should be viewed as remuneration
for referring or influencing referrals of patients or services covered by such
programs as prohibited by the Anti-Kickback Amendments. The Company is not a
provider or supplier of services or items reimbursed by Medicare or state health
programs.
In 1991, the Inspector General of the United States Department of Health
and Human Services published "Safe Harbor Regulations," defining safe harbors
for certain arrangements that do not violate the Anti-Kickback Amendments. One
of the safe harbors specifically provided is a safe harbor for personal services
and management contracts. Under this safe harbor, "remuneration" prohibited by
the Anti-Kickback Amendments does not include any payment made by a principal to
an agent as compensation for services of the agent as long as certain standards
are met. To the Company's knowledge, there have been no agency interpretations
or case law decisions of management agreements similar to the Company's that
would indicate that such agreements do not fall within a safe harbor. Further,
the Company believes that since it is not a provider of medical services, and is
not in a position to refer patients to any particular medical practice, the
remuneration it receives for providing services does not violate the Anti-
Kickback Amendments.
Prohibitions on Certain Referrals. The Omnibus Budget Reconciliation Act
of 1993 ("OBRA") includes a provision that significantly expands the scope of
the Ethics in Patient Referral Act, also known as the "Stark Bill." The Stark
Bill originally prohibited a physician from referring a Medicare or Medicaid
patient to any entity for the provision of clinical laboratory services if the
physician or a family member of the physician had an ownership interest or
compensation relationship with the entity. The revisions to the Stark Bill
prohibit a referral to an entity in which the physician or a family member has
an ownership interest or compensation relationship if the referral is for any of
a list of "designated health services." In January 1998, the Health Care
Financing Administration issued proposed regulations to the Stark Bill. It is
not yet possible to predict whether these proposed regulations will be adopted
or, if adopted, what their final form, effective dates and impact on the Company
will be.
4
<PAGE>
Prohibitions on Certain Compensation Arrangements. The OBRA legislation
also prohibits physician group practices from developing compensation or bonus
arrangements that are directly related to the volume or value of referrals by a
physician in the group for designated health services.
Reimbursement Requirements. In order to participate in the Medicare and
Medicaid programs, the Company's affiliated physicians must comply with
stringent reimbursement regulations, including those that require many health
care services to be conducted "incident to" a physician's supervision.
Satisfaction of all reimbursement requirements is required under the Company's
compliance program. The Company believes that its affiliated physicians are in
compliance with the reimbursement requirements; however, affiliated physicians'
failure to comply with these requirements could negatively affect the Company's
results of operations.
Antitrust. The Company and its affiliated physician groups are subject to
a range of antitrust laws that prohibit anti-competitive conduct, including
price fixing, concerted refusals to deal and division of markets. The Company
believes it is in compliance with these laws, but there can be no assurance that
a review of the Company's business would not result in a determination that
could adversely affect the operations of the Company and its affiliated
physician groups.
Regulatory Compliance. The Company recognizes that health care regulations
will continue to change and, as a result, regularly monitors developments in
health care law. The Company expects to modify its agreements and operations
from time to time as the business and regulatory environment changes. While the
Company believes it will be able to structure all of its agreements and
operations in accordance with applicable law, there can be no assurance that its
arrangements will not be successfully challenged.
Executive Officers of the Registrant
<TABLE>
<CAPTION>
Name, Age, and Position Business Experience
----------------------- --------------------
<S> <C>
R. DALE ROSS, age 52 Mr. Ross was self-employed from April 1990 until joining the Company. From
Chairman of the Board of Directors and Chief December 1982 until April 1990, Mr. Ross was employed by HMSS, Inc., a home
Executive Officer since December 1992 infusion therapy company. Mr. Ross founded HMSS, Inc. and served as its
President and Chief Executive Office and as a director.
LLOYD K. EVERSON, M.D., age 55 Dr. Everson received his medical degree from Harvard Medical School and his
President since November 1993 oncology training at Memorial Sloan Kettering National Cancer Institute. He
is board certified in medical oncology. Prior to joining the Company, Dr.
Everson served as the Medical Director for the Indiana Regional Cancer
Center and was President of LKE Consulting Services. Dr. Everson has
published widely in the field of oncology and is a member of numerous
professional associations, including the American Society of Clinical
Oncology, Association of Community Cancer Centers and American College of
Physicians. He also has served as President of the Association of Community
Cancer Centers and as Associate Chairman for Community Programs for the
Eastern Cooperative Oncology Group.
DAVID S. CHERNOW, age 42 From March 1992 until joining the Company, Mr. Chernow was a Real Estate
Vice President of Corporate Development and Development Consultant at Hematology Oncology Associates, an oncology group
Chief Development Officer since January 1993 affiliated with the Company in Denver, Colorado. From March 1990 until
March 1992, he was employed by Lamar Companies, a real estate investment
company located in Denver, as Vice President of Operations.
</TABLE>
5
<PAGE>
<TABLE>
<S> <C>
L. DUANE CHOATE, age 40 Mr. Choate has been employed by the Company in various positions since March
Vice President of Practice Operations since 1993. From 1991 to 1993, Mr. Choate was employed by Discovery Group, Inc.,
November 1998 a direct marketing company, as President. From October 1984 until April
1990, he was employed by HMSS, Inc. in various finance positions.
R. ALLEN PITTMAN, age 51 From May 1991 until joining the Company, Mr. Pittman was employed as Vice
Vice President of Corporate Services since President of Human Resources by Option Care, Inc., a national home infusion
January 1993 therapy franchiser. From November 1987 until April 1991, Mr. Pittman was
employed by HMSS, Inc., where he served as Vice President of Human Resouces.
L. FRED POUNDS, age 51 From June 1990 until joining the Company, Mr. Pounds was the principal of
Vice President of Finance, Chief Financial Pounds & Associates, a health care consulting company. From January 1987 to
Officer and Treasurer since January 1993 May 1990, Mr. Pounds was President and Chief Operating Officer of Avanti
Health Systems, Inc., a managed care and physician practice management
company. From September 1969 to January 1987, Mr. Pounds was employed by
Price Waterhouse LLP in various positions, including partner in charge of
the Southwest Area Health Care Group.
LEO E. SANDS, age 51 From July 1991 until joining the Company, Mr. Sands was a principal of
Vice President of Planning, Chief Compliance Altech, Inc., a health care consulting company. From March 1983 to April
Officer and Secretary since November 1992 1986 and from May 1988 to June 1991, Mr. Sands was employed by HMSS, Inc.
in various positions, ultimately serving as Vice President of Business
Development of HMSS Infusion Affiliates, Inc.
</TABLE>
Employees
As of December 31, 1998, the Company employed 1,293 people. In addition,
as of December 31, 1998, the affiliated physician groups employed 1,907 people
(excluding the affiliated physicians). Under the terms of the management
agreements with the affiliated physician groups, the Company is responsible for
the practice compensation and benefits of the groups' non-physician medical
personnel. No employee of the Company or of any affiliated group is a member of
a labor union or subject to a collective bargaining agreement. The Company
considers its relations with its employees to be good.
Service Marks
The Company has registered the service marks "American Oncology Resources"
and "AOR" with the United States Patent and Trademark Office.
ITEM 2. PROPERTIES
The Company leases its corporate offices in Houston, Texas, where the
Company's headquarters are located. The Company or its affiliated physician
groups also own, lease, sublease or occupy the facilities where the affiliated
physician groups provide medical services. In connection with the development
of integrated cancer centers, the Company has acquired land valued at
approximately $2.2 million. The Company anticipates that, as its affiliated
group practices grow, expanded facilities will be required.
At December 31, 1998, the Company operated sixteen cancer centers and had
eight cancer centers under development. Of the sixteen cancer centers operated
by the Company, thirteen are leased by the Company and three are owned. The
following table contains information concerning the Company's cancer centers:
6
<PAGE>
<TABLE>
<CAPTION>
Location Size Date Opened or Acquired Owned/Leased
-------- ---- ----------------------- ------------
<S> <C> <C> <C>
Tucson, Arizona 9,444 Sq. Ft. January 1995 Leased
Rexford, New York 14,100 Sq. Ft. October 1995 Leased
Latham, New York 12,877 Sq. Ft. October 1995 Leased
Green Valley, Arizona 7,604 Sq. Ft. October 1997 Owned
Dunedin, Florida 3,335 Sq. Ft. November 1997 Leased
Tampa, Florida 4,000 Sq. Ft. November 1997 Leased
New Port Richey, Florida 10,125 Sq. Ft. November 1997 Leased
Sun City, Florida 4,345 Sq. Ft. November 1997 Leased
Hancock, Indiana 7,337 Sq. Ft. February 1998 Leased
Stillwater, Oklahoma 11,610 Sq. Ft. February 1998 Owned
Oklahoma City, Oklahoma 15,700 Sq. Ft. March 1998 Owned
Aurora, Colorado 13,200 Sq. Ft. July 1998 Leased
Tulsa, Oklahoma 13,200 Sq. Ft. August 1998 Leased
Indianapolis, Indiana 12,000 Sq. Ft. August 1998 Leased
New Braunfels, Texas 8,864 Sq. Ft. August 1998 Leased
Thornton, Colorado 11,400 Sq. Ft. October 1998 Leased
</TABLE>
ITEM 3. LEGAL PROCEEDINGS
The provision of medical services by the Company's affiliated physicians
entails an inherent risk of professional liability claims. The Company does not
control the practice of medicine by physicians or the compliance with certain
regulatory and other requirements directly applicable to physicians and
physician groups. Because the Company's affiliated physician groups purchase
and resell pharmaceutical products, they face the risk of product liability
claims. Although the Company has not been a party to any claims, suits or
complaints relating to services and products provided by the Company or
physicians affiliated with the Company, there can be no assurances that such
claims will not be asserted against the Company in the future. The Company
maintains insurance coverage that it believes to be adequate both as to risks
and amounts. In addition, pursuant to the management services agreements with
the affiliated physician groups, the affiliated practices and the Company are
required to maintain comprehensive professional liability insurance. Successful
malpractice claims asserted against the Company or one of the affiliate
physician groups could, however, have a material adverse effect on the Company.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
No matters were submitted to a vote of security holders during the fourth
quarter of 1998.
PART II
ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
The Company's Common Stock is traded on The Nasdaq Stock Market under the
symbol "AORI". The high and low closing sale prices of the Common Stock, as
reported by The Nasdaq Stock Market, were as follows for the quarterly periods
indicated.
<TABLE>
<CAPTION>
Year Ended December 31, 1997 High Low
---- ---
<S> <C> <C>
Fiscal Quarter Ended March 31, 1997 $11.00 $ 8.75
Fiscal Quarter Ended June 30, 1997 $16.88 $ 7.44
Fiscal Quarter Ended September 30, 1997 $17.38 $13.31
Fiscal Quarter Ended December 31, 1997 $19.00 $12.75
</TABLE>
7
<PAGE>
<TABLE>
<CAPTION>
Year Ended December 31, 1998
<S> <C> <C>
Fiscal Quarter Ended March 31, 1998 $17.38 $12.38
Fiscal Quarter Ended June 30, 1998 $15.75 $11.13
Fiscal Quarter Ended September 30, 1998 $13.75 $ 8.13
Fiscal Quarter Ended December 31, 1998 $15.00 $ 8.63
</TABLE>
As of February 24, 1999, there were approximately 8,800 holders of the
Common Stock. The Company has not declared or paid any cash dividends on its
Common Stock. The payment of cash dividends in the future will depend on the
Company's earnings, financial condition, capital needs and other factors deemed
pertinent by the Company's board of directors, including the limitations, if
any, on the payment of dividends under state law and then-existing credit
agreements. It is the present policy of the Company's board of directors to
retain earnings to finance the operations and expansion of the Company's
business. The Company's credit facility currently prohibits the payment of cash
dividends. See "Management's Discussion and Analysis of Financial Condition and
Results of Operations Liquidity and Capital Resources."
RECENT SALES OF UNREGISTERED SECURITIES
In connection with each affiliation transaction between the Company and an
oncology group, the Company purchases the nonmedical assets of, and enters into
a long-term management agreement with, that oncology group. In consideration
for that arrangement, the Company typically pays cash, issues subordinated
promissory notes (in general, payable on each of the third through seventh
anniversaries of the closing date at an annual interest rate of seven percent)
and unconditionally agrees to deliver shares of Common Stock at specified future
dates (in general, on each of the third through fifth anniversaries of the
closing date).
The following table describes all private placements by the Company of its
securities during 1998. Each sale was a private placement made in connection
with a physician transaction, described in general in the preceding paragraph,
to affiliated oncologists, the overwhelming majority of whom are accredited
investors. No underwriter was involved in any such sale, and no commission or
similar fee was paid with respect thereto. Each sale was not registered under
the Securities Act of 1933 in reliance on Section 4(2) of such Act and Rule 506
enacted thereunder.
<TABLE>
<CAPTION>
Number of Shares of Aggregate Principal
Date of Transaction Number of Physicians Common Stock(1) Amount of Notes
- ------------------- -------------------- --------------- ---------------
<S> <C> <C> <C>
3/98 3 61,276 $1,140,000
3/98 6 115,758 1,504,000
5/98 6 111,923 778,000
6/98 1 16,824 300,000
6/98 2 39,077 549,000
6/98 1 6,320 --
7/98 1 20,058 251,000
8/98 3 41,136 901,000
9/98 1 88,250 1,689,000
12/98 1 62,029 450,000
12/98 1 10,000 --
</TABLE>
- --------------
(1) In connection with each affiliation transaction, the Company unconditionally
agrees to deliver shares of Common Stock at specified future dates
(typically on each of the third through fifth anniversaries of the closing
date).
8
<PAGE>
ITEM 6. SELECTED FINANCIAL DATA
The selected consolidated financial information of the Company set forth below
is qualified by reference to, and should be read in conjunction with,
"Management's Discussion and Analysis of Financial Condition and Results of
Operations" and the Consolidated Financial Statements and notes thereto included
elsewhere in this report.
<TABLE>
<CAPTION>
Year Ended December 31,
-----------------------------------------------------------
1998 1997 1996 1995 1994
-------- -------- -------- ------ -------
(in thousands, except per share data)
<S> <C> <C> <C> <C> <C>
STATEMENT OF OPERATIONS DATA:
Revenue................................. $455,952 $321,840 $205,460 $99,174 $20,410
Operating expenses:
Pharmaceuticals and supplies........... 207,930 144,890 85,210 35,763 7,575
Practice compensation and benefits..... 86,136 61,296 41,350 19,766 4,001
Other practice costs................... 51,769 35,090 23,495 12,032 2,258
General and administrative............. 26,201 21,174 14,095 9,406 4,367
Depreciation and amortization.......... 23,287 14,177 9,343 4,655 746
-------- -------- -------- ------- -------
395,323 276,627 173,493 81,622 18,947
-------- -------- -------- ------- -------
Income from operations.................. 60,629 45,213 31,967 17,552 1,463
Interest income......................... 222 348 1,062 2,007 143
Interest expense........................ (12,096) (8,715) (4,307) (3,690) (237)
Other, net.............................. 1,600(1)
-------- -------- -------- ------- -------
Income before taxes..................... 48,755 36,846 28,722 17,469 1,369
Income taxes............................ 18,527 13,979 11,072 5,852 126
-------- -------- -------- ------- -------
Net income.............................. $ 30,228 $ 22,867 $ 17,650 $11,617 $ 1,243
======== ======== ======== ======= =======
Net income per share basic.............. $ 0.63 $ 0.50 $ 0.40 $ 0.33 $ 0.08
======== ======== ======== ======= =======
Shares used in per share computations -
basic.................................. 48,293 45,571 44,228 35,559 15,926
======== ======== ======== ======= =======
Net income per share diluted............ $ 0.61 $ 0.48 $ 0.37 $ 0.30 $ 0.07
======== ======== ======== ======= =======
Shares used in per share computations -
diluted................................ 49,845 48,100 47,549 39,318 16,995
======== ======== ======== ======= =======
</TABLE>
<TABLE>
<CAPTION>
December 31,
---------------------------------------------------------
1998 1997 1996 1995 1994
-------- -------- -------- -------- -------
(in thousands)
<S> <C> <C> <C> <C> <C>
BALANCE SHEET DATA:
Working capital...................... $ 82,016 $ 43,864 $ 42,972 $ 59,724 $ 6,653
Management service agreements, net... 338,673 326,295 240,034 164,522 40,444
Total assets......................... 568,100 483,893 339,400 272,359 55,709
Long-term debt (2)................... 173,140 139,716 81,707 44,190 18,703
Stockholders' equity................. 294,387 263,994 221,854 191,180 30,977
</TABLE>
- --------------
(1) Consists of life insurance proceeds of $2,091,000, less lease termination
costs of $491,000.
(2) Excludes current maturities of long-term debt.
9
<PAGE>
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
Introduction
AOR is a cancer management company and provides comprehensive management
services under long-term agreements to oncology practices. These practices
provide a broad range of medical services to cancer patients, integrating the
specialties of medical and gynecological oncology, hematology, radiation
oncology, diagnostic radiology and stem cell transplantation. Since the
Company's incorporation in October 1992, it has grown rapidly from managing six
affiliated physicians in one state to 380 affiliated physicians in 18 states as
of March 12, 1999:
<TABLE>
<CAPTION>
MARCH 12, DECEMBER 31,
--------- ------------------
1999 1998 1997 1996
---- ---- ---- ----
<S> <C> <C> <C> <C>
Affiliated physicians..................... 380 358 304 227
States.................................... 18 18 16 15
</TABLE>
Under the terms of the management agreements, the Company provides
comprehensive management services to its affiliated physician groups, including
operational and administrative services, and furnishes personnel, facilities,
supplies and equipment. The physician groups, in return, agree to practice
medicine exclusively in affiliation with the Company. Substantially all of the
Company's revenue consists of management fees paid under the terms of the
management agreements. Management fees include all practice costs (other than
amounts retained by physicians), a fixed monthly fee, an amount equal to 7% of
each affiliated physician group's net revenue (in most states) and, if certain
financial criteria are satisfied, a performance fee. The management agreements
permit the affiliated physician group to retain a specified percentage of the
group's net revenues (generally 23%) for physician salaries, and payment of such
salaries is given priority over payment of the management fee. For the years
ended December 31, 1998 and 1997, none of the Company's affiliated physician
groups contributed more than 10% of the Company's revenue. For the year ended
December 31, 1996, only one of the Company's affiliated physician groups
contributed more than 10% of the Company's revenue.
In 1998, the payor mix of the affiliated physician groups' medical practice
revenue, expressed as a percentage, was 34% for Medicare and Medicaid, 47% for
managed care and 19% for private insurance and other payors. In 1997, the payor
mix of the affiliated physician groups' medical practice revenue, expressed as a
percentage, was 33% for Medicare and Medicaid, 47% for managed care and 20% for
private insurance and other payors. In 1996, the payor mix of the affiliated
physician groups' medical practice revenue was 33% for Medicare and Medicaid,
45% for managed care and 22% for private insurance and other payors. The payor
mix of the affiliated physician groups' medical practice revenue varies among
physician groups and changes as a result of new practice affiliations.
Effective December 11, 1998, the Company entered into a definitive agreement
to merge with Physician Reliance Network, Inc. ("PRN"). As of March 12, 1999,
PRN provided comprehensive management services under long-term agreements to
medical practices comprised of 367 physicians in twelve states. Under the terms
of the merger agreement, holders of PRN common stock will receive a fixed ratio
of 0.94 shares of the Company's common stock for each PRN share held. As a
result, stockholders of the Company and PRN will each own approximately 50% of
the combined company on a diluted basis. Following the merger, PRN will be a
wholly owned subsidiary of the Company. The transaction is expected to be
accounted for under the pooling of interests method of accounting and treated as
a tax-free exchange. Closing of the transaction is anticipated in the second
quarter of 1999, subject to stockholder approval of both companies, regulatory
approval and other customary conditions. After consummation of the transaction,
the Company's financial statements will be retroactively restated to combine the
accounts of the Company and PRN for all periods presented using their historical
basis.
10
<PAGE>
RESULTS OF OPERATIONS
The following table sets forth the percentages of revenue represented by
certain items reflected in the Company's Statement of Operations. The
information that follows should be read in conjunction with the Company's
Consolidated Financial Statements and notes thereto included elsewhere herein.
<TABLE>
<CAPTION>
YEAR ENDED DECEMBER 31,
-----------------------------
1998 1997 1996
---- ---- ----
<S> <C> <C> <C>
Revenue................................... 100.0% 100.0% 100.0%
----- ----- -----
Operating expenses:
Pharmaceuticals and supplies......... 45.6 45.0 41.5
Practice compensation and benefits... 18.9 19.0 20.1
Other practice costs................. 11.4 10.9 11.4
General and administrative........... 5.7 6.6 6.9
Depreciation and amortization........ 5.1 4.4 4.5
Net interest.............................. 2.6 2.6 1.6
----- ----- -----
Income before income taxes................ 10.7 11.5 14.0
Income taxes.............................. 4.1 4.4 5.4
----- ----- -----
Net income................................ 6.6% 7.1% 8.6%
===== ===== =====
</TABLE>
1998 COMPARED TO 1997
The Company affiliated with eleven and thirteen oncology groups in 1998 and
1997, respectively, the results of which are included in the Company's operating
results from the dates of affiliation. Changes in results of operations year to
year were caused in part by affiliations with these oncology practices.
Revenue. Revenue increased from $321.8 million in 1997 to $456.0 million
in 1998, an increase of $134.2 million or 41.7%. Revenue for markets under
management in 1997 and 1998 increased $95.6 million or 29.7% over the same
period from the prior year. This growth was the result of increases in patient
volume, expansion of services, recruitment of or affiliation with additional
physicians and, to a lesser extent, increases in charges for certain physician
services. The remaining $38.6 million of revenue growth was attributable to
affiliations with oncology practices in new markets.
Pharmaceuticals and Supplies. Pharmaceuticals and supplies, which include
the drugs, medications and other supplies used by affiliated physician groups,
increased from $144.9 million for 1997 to $207.9 million for 1998, an increase
of $63.0 million or 43.5%. This increase was principally attributable to the
same factors that caused revenue to increase. As a percentage of revenue,
pharmaceuticals and supplies increased from 45.0% for 1997 to 45.6% for 1998.
This increase was primarily due to a shift in the revenue mix to a higher
percentage of drug revenue, the introduction of a number of new chemotherapy
agents and, to a lesser extent, lower reimbursement from payors. Management
expects that third-party payors will continue to negotiate the reimbursement
rate for medical services, pharmaceuticals (including chemotherapy drugs) and
other supplies, with the goal of lowering reimbursement and utilization rates,
and that such lower reimbursement and utilization rates as well as shifts in
revenue mix may continue to adversely impact the Company's margins with respect
to such items.
Practice Compensation and Benefits. Practice compensation and benefits,
which include the salaries, wages and benefits of the affiliated physician
groups' employees (excluding affiliated physicians) and the Company's employees
located at the affiliated physician practice sites and business offices,
increased from $61.3 million in 1997 to $86.1 million in 1998, an increase of
$24.8 million or 40.5%. This increase was principally attributable to the same
factors that caused revenue to increase. As a percentage of revenue, practice
compensation and benefits decreased from 19.0% for 1997 to 18.9% for 1998.
Other Practice Costs. Other practice costs, which consist of rent,
utilities, repairs and maintenance, insurance and other direct practice costs,
increased from $35.1 million in 1997 to $51.8 million in 1998, an increase of
$16.7 million or 47.6%. This increase was principally attributable to the same
factors that caused revenue to increase. As a percentage of revenue, other
practice costs increased from 10.9% for 1997 to 11.4% for 1998.
General and Administrative. General corporate expenses increased from
$21.2 million in 1997 to $26.2 million in 1998, an increase of $5.0 million or
23.6%. This increase was primarily attributable to the addition of personnel
and greater
11
<PAGE>
support costs associated with the Company's growth since December 31, 1997. As a
percentage of revenue, general and administrative expenses decreased from 6.6%
for 1997 to 5.7% for 1998, primarily as a result of economies of scale.
Depreciation and Amortization. Depreciation and amortization expenses
increased from $14.2 million in 1997 to $23.3 million in 1998, an increase of
$9.1 million or 64.1%. As a percentage of revenue, depreciation and
amortization expenses increased from 4.4% for 1997 to 5.1% for 1998. This
increase is primarily attributable to decreasing the amortization period for
management services agreements from 40 years to 25 years effective July 1, 1998.
Affiliations with new physician groups, and investments in equipment, leasehold
improvements and management information systems also contributed to the
increase.
Interest. Net interest expense increased from $8.4 million in 1997 to
$11.9 million in 1998, an increase of $3.5 million or 41.7%. The increase was
the result of higher levels of debt, principally incurred to finance
transactions with eleven oncology groups during 1998. As a percentage of
revenue, net interest expense remained the same at 2.6% in 1997 and 1998.
Indebtedness to physicians decreased from approximately $94.7 million at
December 31, 1997 to approximately $80.6 million at December 31, 1998.
Income Taxes. Income tax expense increased from the prior year as a result
of the Company's increased profitability. For 1998, the Company recognized a
tax provision of $18.5 million resulting in an effective rate of 38%, which was
unchanged from 1997.
Net Income. Net income increased from $22.9 million in 1997 to $30.2
million in 1998, an increase of $7.3 million or 31.9%. As a percentage of
revenue, net income declined from 7.1% to 6.6%, principally as a result of the
decrease in the amortization period for management service agreements from 40
years to 25 years effective July 1, 1998, and to a lesser extent, the
introduction of a number of new, lower margin chemotherapy agents. In response
to this decline, the Company has adopted several strategies. Most importantly,
the Company has formed a number of preferred pharmaceutical relationships and
continues to pursue others. In addition, the Company routinely considers and
implements measures to control general and administrative costs to enable it to
achieve greater economies of scale. Lastly, the Company seeks opportunities to
expand its business in areas that are less affected by lower pharmaceutical
margins, such as radiation oncology, clinical research and data management. The
Company believes that its results of operations and financial condition have
benefited from each of these strategies.
1997 COMPARED TO 1996
The Company affiliated with thirteen and seventeen oncology groups in 1997
and 1996, respectively, the results of which are included in the Company's
operating results from the dates of affiliation. Changes in results of
operations year to year were caused in part by affiliations with these oncology
practices.
Revenue. Revenue increased from $205.5 million in 1996 to $321.8 million
in 1997, an increase of $116.3 million or 56.6%. Revenue for markets under
management in 1996 and 1997 increased $85.5 million or 42% over the same period
from the prior year. The methodology for calculating same market growth for
this period represented a change from the same practice growth disclosed in
prior periods. The Company changed the methodology to more accurately reflect
the revenue growth of a market from period to period as well as the changing
structure of new physician transactions in 1997. Under the revised method,
revenue growth for all practices within a metropolitan service area in which the
Company has operations in both periods is treated as same market growth. Under
the previous methodology, the same practice growth for 1997 over the comparable
period in 1996 would have been a 25% increase in revenue. Same market growth
was the result of expansion of services, increases in patient volume,
recruitment of or affiliation with additional physicians and, to a lesser
extent, increases in charges for certain physician services. The remaining
$30.8 million was attributable to affiliations with oncology practices in new
markets.
Pharmaceuticals and Supplies. Pharmaceuticals and supplies increased from
$85.2 million for 1996 to $144.9 million for 1997, an increase of $59.7 million
or 70.1%. This increase was principally attributable to the same factors that
caused revenue to increase. As a percentage of revenue, pharmaceuticals and
supplies increased from 41.5% for 1996 to 45.0% for 1997. This increase was
primarily due to a shift in the revenue mix to a higher percentage of drug
revenue, the introduction of a number of new chemotherapy agents and, to a
lesser extent, lower reimbursement from payors. Management expects that third-
party payors will continue to negotiate the reimbursement rate for medical
services, pharmaceuticals (including chemotherapy drugs) and other supplies,
with the goal of lowering reimbursement and utilization rates, and that
12
<PAGE>
such lower reimbursement and utilization rates as well as shifts in revenue mix
may continue to adversely impact the Company's margins with respect to such
items.
Practice Compensation and Benefits. Practice compensation and benefits
increased from $41.4 million in 1996 to $61.3 million in 1997, an increase of
$19.9 million or 48.1%. This increase was principally attributable to the same
factors that caused revenue to increase. As a percentage of revenue, practice
compensation and benefits decreased from 20.1% for 1996 to 19.0% for 1997,
primarily as a result of economies of scale.
Other Practice Costs. Other practice costs increased from $23.5 million in
1996 to $35.1 million in 1997, an increase of $11.6 million or 49.4%. This
increase was principally attributable to the same factors that caused revenue to
increase. As a percentage of revenue, other practice costs decreased from 11.4%
for 1996 to 10.9% for 1997, primarily as a result of economies of scale.
General and Administrative. General corporate expenses increased from
$14.1 million in 1996 to $21.2 million in 1997, an increase of $7.1 million or
50.4%. This increase was primarily attributable to the addition of personnel
and greater support costs associated with the Company's growth since December
31, 1996. As a percentage of revenue, general and administrative expenses
decreased from 6.9% for 1996 to 6.6% for 1997, primarily as a result of
economies of scale.
Depreciation and Amortization. Depreciation and amortization expenses
increased from $9.3 million in 1996 to $14.2 million in 1997, an increase of
$4.9 million or 52.7%. This increase was primarily attributable to affiliations
with new physician groups, as well as investments in equipment, leasehold
improvements and management information systems during 1997. As a percentage of
revenue, depreciation and amortization decreased form 4.5% for 1996 to 4.4% for
1997.
Interest. Net interest expense increased from $3.2 million in 1996 to $8.4
million in 1997, an increase of $5.2 million or 162.5%. The increase was the
result of higher levels of debt, principally incurred to finance transactions
with thirteen oncology groups during 1997. As a percentage of revenue, net
interest expense increased from 1.6% in 1996 to 2.6% in 1997. Indebtedness to
physicians increased from approximately $66.0 million at December 31, 1996 to
approximately $94.7 million at December 31, 1997.
Income Taxes. Income tax expense increased from the prior year as a result
of the Company's increased profitability. For 1997, the Company recognized a
tax provision of $14.0 million resulting in an effective rate of 38.0% as
compared to a rate of 38.5% for 1996. The decrease in the effective rate was
due primarily to a change in the Company's composition of revenue by state.
Net Income. Net income increased from $17.7 million in 1996 to $22.9
million in 1997, an increase of $5.2 million or 29.4%. As a percentage of
revenue, net income declined from 8.6% to 7.1%. This decline was primarily
attributable to the introduction of a number of new, lower margin chemotherapy
agents and, to a lesser extent, from difficulty in efficiently integrating
practices affiliated with the Company in late 1996 and 1997 and higher discounts
to managed care payors. In response to this decline, the Company has adopted
several strategies. Most importantly, the Company has formed a number of
preferred pharmaceutical relationships and continues to pursue others. In
addition, the Company routinely considers and implements measures to control
general and administrative costs to enable it to achieve greater economies of
scale. Lastly, the Company seeks opportunities to expand its business in areas
that are less affected by lower pharmaceutical margins, such as radiation
oncology, clinical research and data management. The Company believes that its
results of operations and financial condition have benefited from each of these
strategies.
FORWARD-LOOKING STATEMENTS AND RISK FACTORS
The following statements are or may constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995: (i)
certain statements, including possible or assumed future results of operations
of AOR, contained in "Business" and "Management's Discussion and Analysis of
Financial Condition and Results of Operations," and including any statements
contained herein regarding the prospects for any of the Company's services and
the impact of competition; (ii) any statements preceded by, followed by or that
include the words "believes," "expects," "anticipates," "intends" or similar
expressions; and (iii) other statements contained herein regarding matters that
are not historical facts.
Because such statements are subject to risks and uncertainties, actual
results may differ materially from those expressed or implied by such forward-
looking statements. Factors that could cause actual results to differ
materially include,
13
<PAGE>
but are not limited to, those discussed below under "Risk Factors." AOR
stockholders are cautioned not to place undue reliance on such statements, which
speak only as of the date thereof.
The cautionary statements contained or referred to herein should be
considered in connection with any subsequent written or oral forward-looking
statements that may be issued by AOR or persons acting on its behalf. AOR does
not undertake any obligation to release any revisions to or to update publicly
any forward-looking statements to reflect events or circumstances after the date
thereof or to reflect the occurrence of unanticipated events.
RISK FACTORS RELATING TO THE PROPOSED MERGER WITH PRN
Effective December 11, 1998, the Company entered into a definitive
agreement to merge with PRN. Closing of the merger is subject to regulatory and
stockholder approval and other customary conditions. There are a number of
risks relating to the AOR-PRN merger, including the ones discussed below.
We may not achieve expected synergies
We expect the merger to result in synergies and operating efficiencies,
including reduced overhead costs as a percentage of revenue, expanded
operations, enhanced purchasing leverage and improved managed care contracting.
These expected benefits may not be achieved. Whether we ultimately realize these
benefits will depend on a number of factors, many of which are beyond our
control.
Integrating our operations will be difficult and may cause harmful disruptions
to our business
Integrating our operations may distract the attention of management and
other personnel from our day-to-day business activities. In addition, employees
of AOR may be less productive as a result of uncertainty during the integration
process, which may disrupt our business. These disruptions or any other
difficulties with integration could seriously harm the combined company. To
attain the benefits of the merger, we will have to effectively integrate our
operations. In particular, we must integrate our management and other personnel,
our information systems and our financial, accounting and other operational
procedures. This process will require us to bring together nationwide operations
and different corporate and physician cultures. AOR and PRN have each affiliated
with numerous physician practices but neither has attempted a transaction of the
size of the merger.
Costs of integration and transaction expenses will be substantial and could
significantly exceed our expectations
We will incur transaction, integration and restructuring costs in
connection with the merger. These costs will result in one-time charges to our
earnings. We expect these costs to be substantial, and unanticipated additional
expenses related to the merger could cause this amount to increase
significantly. Although it is impossible to determine the actual amount of these
charges until the integration plans are completed, we believe that the total of
these charges will be approximately $28 million. We cannot determine the exact
timing of these expenses at this time, but we anticipate that this aggregate
charge to earnings will be recorded principally in the quarter in which the
merger is consummated.
Loss of our key personnel could adversely affect our business
We must retain senior executives and other key employees to be successful.
We may not be able to retain key employees before or after the merger. The loss
of the services of any key employees or of any significant group of employees
could seriously harm our companies. During the pre-merger and integration
phases, competitors may seek to recruit key employees. Employee uncertainty
regarding the effects of the merger could also cause increased turnover. Our
employees are generally not bound by employment agreements.
Physicians and other third parties may not accept the combined company
AOR and PRN have each tried to build name recognition and physician
acceptance of their respective companies. However, physicians and other third
parties may not accept the combined company, even if they accepted AOR or PRN as
individual companies. We believe that transferring the name recognition from AOR
and PRN to the combined company will be important to maintaining good relations
with our existing physicians and for attracting new physicians. This transition
will
14
<PAGE>
also be important to our efforts to maintain and enhance relationships with
pharmaceutical suppliers, payors and other third parties. We must continue to
provide management, accounting, information and other services well. If we do
not, we may have trouble continuing and improving relationships with third
parties.
RISKS RELATING TO THE BUSINESS OF THE COMPANY
We may not be able to successfully affiliate with new physician groups or
integrate the operations of new affiliations
AOR has grown by affiliating with new physician groups and expanding the
operations of existing affiliated physician groups. We intend to continue to
pursue this growth strategy. Identifying appropriate physician groups and
negotiating affiliations with them can be costly. We may not be able to
affiliate with additional physician groups on desirable terms. We may encounter
difficulties integrating the operations of additional physician groups. Our
failure to successfully integrate newly affiliated physician groups could harm
us.
Our development of new cancer centers could be delayed or result in serious
liabilities
Another growth strategy of AOR is to develop integrated cancer centers. The
development of integrated cancer centers is subject to a number of risks,
including obtaining regulatory approval, delays that often accompany
construction of facilities and environmental liabilities that attach to
operating cancer centers. Any failure or delay in successfully building and
operating integrated cancer centers or in avoiding liabilities from operations
could seriously harm the Company.
Loss of revenues by our affiliated physician groups could decrease the Company's
revenues
AOR's revenue depends on revenue generated by affiliated physician groups.
Loss of revenue by the affiliated physician groups could seriously harm the
Company. It is possible that our affiliated physician groups will not be able to
maintain successful medical practices.
If a significant number of physicians leaves our affiliated practices, the
Company could be seriously harmed
Each of our affiliated practices enters into employment agreements with its
physicians. We and our affiliated practices try to maintain such contracts.
However, if a significant number of physicians terminate their relationships
with our affiliated practices, the Company could be seriously harmed.
Our affiliated practices may be unable to enforce noncompetition provisions with
departed physicians
Most of the employment agreements between the affiliated practices and
their physicians include a clause that prevents the physician from competing
with the practice for a period after termination of employment. We cannot
predict with certainty whether a court will enforce the noncompetition covenants
of the affiliated practices. If practices are unable to enforce the
noncompetition provisions of their employment agreements, the Company could be
seriously harmed.
If our physician groups terminated their management agreements, we would be
seriously harmed
Our affiliated physician groups may attempt to terminate their management
agreements. If any of our larger groups were to succeed in such a termination,
we could be seriously harmed. We are aware that some physician groups have
attempted to end or restructure their affiliations with other practice
management companies when they do not have a contractual right to do so. Such
groups argue that their affiliations violate some aspect of health care law. For
example, some physician groups affiliated with other physician practice
management companies have claimed that the management fee arrangements violate
federal or state prohibitions on splitting fees with physicians. If our
affiliated physicians or practices were able to successfully make such an
argument, the effect on our affiliations could harm us.
15
<PAGE>
Loss of revenue by affiliated physician groups caused by the cost containment
efforts of third-party payors could seriously harm us
Loss of revenue by affiliated physician groups caused by the cost
containment efforts of third-party payors could seriously harm us. Physician
groups typically bill various third-party payors, such as governmental programs
like Medicare and Medicaid, private insurance plans and managed care plans, for
the health care services provided to their patients. These third-party payors
negotiate the prices charged for medical services and supplies to lower the cost
of health care services and products paid for by them. Third-party payors also
try to influence legislation to lower costs. Reimbursement rates for
pharmaceuticals have a major impact on our affiliated practices. Third-party
payors can also deny reimbursement for medical services and supplies if they
determine that a treatment was not appropriate. Our affiliated practices' also
derive a significant portion of their revenues from governmental programs.
Reimbursement by governmental programs generally is not subject to negotiation
and is established by governmental regulation.
Managed care and capitation can adversely impact our business
A loss in revenues, or a failure to contain costs, by our affiliated
practices under managed care and capitated arrangements could cause our revenues
to be substantially diminished. Under capitation arrangements, health care
providers do not receive a fee for each medical service provided but instead
receive an aggregate fee for treating a defined population of patients. As a
result, health care providers bear the risk that the costs of providing medical
services to the determined population will exceed the payments received. The
ability of the providers to effectively manage the per patient costs affects
profitability. Although the majority of the revenues of our affiliated practices
come from non-capitated services, we expect capitated arrangements to become a
bigger part of our business in the future.
We could become subject to costly insurance regulations
The Company and its affiliated physician groups may enter into capitation
contracts with managed care organizations. The Company and our affiliated groups
would assume risk in connection with providing healthcare services under these
arrangements. If we or our affiliated groups are considered to be in the
business of insurance as a result of entering into these capitation
arrangements, we and our affiliated groups could become subject to a variety of
regulatory and licensing requirements applicable to insurance companies that
could harm the Company.
If our operations are deemed by regulators not to comply with applicable
regulations, or if restrictive new regulations are passed, we may be seriously
harmed
There can be no assurance that a review of our business or our affiliated
physician groups by courts or by regulatory authorities would not result in
determinations that could seriously harm our operations. Further, the health
care regulatory environment could change and restrict our existing operations or
potential for expansion. The health care industry is highly regulated. We
believe our businesses and the practices of our affiliated physician groups
operate in material compliance with these regulations. However, the
relationships between us and our affiliated physician groups are unique. Many
aspects of these relationships have not been subject to judicial or regulatory
interpretation. There are currently several federal and state initiatives
designed to amend regulations relating to health care. However, we cannot
predict whether any such initiatives will be enacted as legislation or, if
enacted, what their form, effective dates or impact on us will be.
Our business, and the business of our affiliated practices, could be harmed by
competition with other businesses
Our business, and the business of our affiliated practices, could be harmed
by competition with other businesses. The business of providing health care
related services and facilities is very competitive. Many competitors manage
oncology practices, and several health care companies with longer operating
histories and more resources are currently providing at least some management
services to oncologists. There are also other companies with substantial
resources that may decide to enter the cancer management business. Furthermore,
our revenues depend on the continued success of our affiliated physician groups.
The physician groups face competition from several sources, including sole
practitioners, single- and multi-specialty groups, hospitals and managed care
organizations.
16
<PAGE>
Our success depends on our key personnel, and we may not be able to hire enough
qualified personnel to meet our hiring needs
We will be harmed if we cannot hire and retain suitable executives and
other personnel. We believe that our success will depend on continued employment
of our executive management team. If one or more members of our management team
become unable or unwilling to continue in their present positions, we could be
harmed.
We and our affiliated practices may become subject to harmful lawsuits
Successful malpractice or products liability claims asserted against the
physician groups or us could seriously harm us. We and our affiliated physician
groups are at risk of malpractice and other lawsuits because they provide health
care services to the public. In addition, managed care providers and physician
practice management companies are increasingly subject to liability claims
arising from physician compensation arrangements and other activities designed
to control costs by reducing services. A successful claim on this basis against
us or an affiliated physician group could harm us. Lawsuits, if successful,
could result in damage awards in excess of the limits of our insurance coverage.
Insurance against losses related to claims of this type is expensive and the
cost varies widely from state to state. In addition, our affiliated physicians
prescribe and dispense pharmaceuticals and, therefore, could be subject to
products liability claims. We and our affiliated physician groups maintain
liability insurance in amounts and coverages we consider appropriate.
Our computer systems and those of our key suppliers and service providers may
not be year 2000 compliant, which may cause system failures and disruptions of
operations
Many existing computer programs use only two digits to identify a year in a
data field. These programs were designed and developed without considering the
impact of the upcoming change in the century. If not corrected, many computer
applications could fail or create erroneous results by or at the Year 2000 or
earlier. The Year 2000 issue affects us in that our business is dependent on
information technology, such as management information systems, financial and
accounting systems, and other equipment systems that may have Y2K related
problems. The failure of our information technology systems to be Year 2000
compliant could have a material adverse effect on our business, financial
condition or results of operations. In addition, the noncompliance of any of our
significant vendors, third-party or governmental payors could have a material
adverse effect on our business, financial condition or results of operations.
Due to the general uncertainty inherent in the year 2000 problem, resulting in
part from the uncertainty of the year 2000 readiness of third-party suppliers,
governmental agencies (in particular, the agencies responsible for administering
Medicare and Medicaid) and customers, we are unable to determine at this time
whether the consequences of year 2000 failures will seriously harm us.
The amortization period for our intangible assets may be reduced, which would
reduce our earnings
In connection with our affiliations with physician practices, AOR records
an intangible amount for the price paid for assets less the value of the
tangible assets acquired. AOR has amortized, and we will continue to amortize,
these intangible assets. This results in periodic non-cash charges to our
earnings. During 1998, AOR shortened the amortization period of its intangible
assets to 25 years. However, if the amortization period is successfully
challenged by regulatory authorities or there is a change in accounting
treatment for such intangibles, we would likely be required to reduce further
the number of years that the intangibles are amortized against our earnings.
This would increase the amount of amortization expense charged against earnings
each year. This increased charge, while non-cash in nature, could significantly
reduce our earnings and seriously harm our business. We expect these non-cash
amortization charges to increase in the future as we continue our affiliation
strategy. In the event that we determine that the value of the intangible assets
related to any specific affiliation is impaired, we could be required to reduce
the value of that asset, which would result in a charge to earnings.
Our stock price may fluctuate significantly, which may make it difficult to
resell your shares when you want to at prices you find attractive
The market price of AOR common stock has been highly volatile. This
volatility may adversely affect the price of our common stock in the future. You
may not be able to resell your shares of common stock following periods of
volatility
17
<PAGE>
because of the market's adverse reaction to this volatility. We anticipate that
this volatility, which frequently affects the stock of health care service
companies, will continue. Factors that could cause such volatility include:
. Our quarterly operating results,
. Deviations in results of operations from estimates of securities analysts
(which the Company neither endorses nor accepts the responsibility for
such estimates),
. General economic conditions or economic conditions specific to the health
care services industry and
. Other developments affecting competitors or us.
On occasion the equity markets, and in particular the markets for physician
management company stocks, have experienced significant price and volume
fluctuations. These fluctuations have affected the market price for many
companies' securities even though the fluctuations are often unrelated to the
companies' operating performance.
Our shareholder rights plan and anti-takeover provisions of the certificate of
incorporation, bylaws and Delaware law could adversely impact a potential
acquisition by third parties
Our shareholder rights plan and anti-takeover provisions of the certificate
of incorporation, bylaws and Delaware law could adversely impact a potential
acquisition by third parties. If the merger with PRN is effected, the combined
company will have a staggered board of directors, with three classes each
serving a staggered three-year term. This classification has the effect of
generally requiring at least two annual stockholder meetings, instead of one, to
replace a majority of the members of the board of directors. If the merger with
PRN is effected, the combined company's certificate of incorporation will also
provide that stockholders may act only at a duly called meeting and that
stockholders' meetings may not be called by stockholders. These provisions could
discourage potential acquisition proposals and could delay or prevent a change
in control of the combined company. These provisions are intended to increase
the likelihood of continuity and stability in our board of directors and in the
policies formulated by them to discourage certain types of transactions that may
involve an actual or threatened change of control of the Company, reduce our
vulnerability to an unsolicited acquisition proposal and discourage certain
tactics that may be used in proxy fights. However, these provisions could have
the effect of discouraging others from making tender offers for our shares, and,
as a consequence, they inhibit fluctuations in the market price of the Company's
shares that could result from actual or rumored takeover attempts. Such
provisions also may have the effect of preventing changes in the management of
the Company.
In addition, other provisions of the Company's certificate of incorporation
and certain provisions of Delaware law may make it difficult to change control
of the Company and to replace incumbent management. For example, the Company's
certificate of incorporation permits the board of directors, without stockholder
approval, to issue additional shares of common stock or to establish one or more
classes or series of preferred stock with characteristics determined by the
board. AOR has also adopted a shareholder rights plan, which would significantly
inhibit the ability of another entity to acquire control of the Company through
a tender offer or otherwise without the approval of the Company's board of
directors. These provisions could limit the price that certain investors might
be willing to pay in the future for shares of common stock.
We have not paid dividends and do not expect to in the future, which means that
the value of our shares cannot be realized except through sale
AOR has never declared or paid cash dividends. We currently expect to
retain earnings for our business and do not anticipate paying dividends on our
common stock at any time in the foreseeable future. Because we do not anticipate
paying dividends, it is likely that the only opportunity to realize the value of
our common stock will be through a sale of those shares. The decision whether to
pay dividends on common stock will be made by the board of directors from time
to time in the exercise of its business judgment. The Company is currently
precluded from paying dividends by the terms of its credit facilities.
18
<PAGE>
SUMMARY OF OPERATIONS BY QUARTER
The following table represents unaudited quarterly results for 1998 and
1997. The Company believes that all necessary adjustments have been included in
the amounts stated below to present fairly the quarterly results when read in
conjunction with the Consolidated Financial Statements and that all adjustments
are of a normal recurring nature. Results of operations for any particular
quarter are not necessarily indicative of operations for a full year or
predictive of future periods.
<TABLE>
<CAPTION>
1998 QUARTER ENDED 1997 QUARTER ENDED
----------------------------------------- -------------------------------------
DEC 31 SEP 30 JUN 30 MAR 31 DEC 31 SEP 30 JUN 30 MAR 31
-------- -------- -------- -------- ------- ------- ------- -------
(In thousands, except per share data)
<S> <C> <C> <C> <C> <C> <C> <C> <C>
Net revenue.............................. $125,126 $118,263 $111,614 $100,949 $89,626 $82,293 $79,525 $70,396
Income from operations................... 15,962 14,964 15,662 14,041 12,468 11,513 11,343 9,889
Net income............................... 8,017 7,448 7,892 6,871 6,166 5,910 5,719 5,072
Net income per share-basic............... .18 .15 .16 .14 .13 .13 .13 .11
Net income per share-diluted............. .16 .15 .16 .14 .13 .12 .12 .11
</TABLE>
LIQUIDITY AND CAPITAL RESOURCES
The Company requires capital primarily to enter into management services
agreements with, and to purchase the nonmedical assets of, oncology medical
practices. During 1998, the Company paid total consideration of $29.5 million in
connection with affiliations with eleven physician groups, including cash and
transaction costs of $14.5 million. During 1997, the Company paid total
consideration of $101.7 million in connection with affiliations with thirteen
physician groups, including cash and transaction costs of $33.2 million.
To fund its growth and development, the Company has satisfied its
transaction and working capital needs through debt and equity financings and
borrowings under a $150 million syndicated revolving credit facility ("Credit
Facility") with First Union National Bank ("First Union"), as agent for the
various lenders. In addition, as part of the Credit Facility the Company has a
$75 million leasing facility that is related to its integrated cancer centers.
During 1998, the Company borrowed $38 million, net, under the Credit
Facility to fund medical practice transactions, the development of integrated
cancer centers and the purchase of its common stock under the Company's stock
repurchase program. Borrowings under the Credit Facility bear interest at a
rate equal to a rate based on prime rate or the London Interbank Offered Rate,
based on a defined formula. The Credit Facility contains affirmative and
negative covenants, including the maintenance of certain ratios, restriction on
sales, leases or other dispositions of properties, restrictions on other
indebtedness and on the payment of dividends. The Company's management services
agreements and the capital stock of the Company's subsidiaries are pledged as
security under the Credit Facility. The Company is currently in compliance with
the Credit Facility covenants, with additional capacity under the Credit
Facility of $46 million at December 31, 1998.
The Company has relied primarily on management fees received from its
affiliated physician groups to fund its operations. While the obligation of
the affiliated practice groups to pay these fees is unsecured, the Company is
entitled to purchase the accounts receivable of the practice for an amount that
is net of such management fee. Since the Company typically effects these
purchases frequently, the amounts due to the Company from its affiliated
physician groups and to such groups from the Company are each short-term
obligations.
Cash provided by operating activities was $37.7 million in 1998, an
increase of $4.3 million, or 12.9%, from 1997. The increase was due to higher
profitability offset by changes in working capital. Cash used in investing
activities was $36.7 million in 1998, compared to $54.6 million in 1997. This
decrease was attributable to a lower level of medical practice transactions in
1998. Cash provided by financing activities was $4.7 million in 1998 compared
to $22.8 million in 1997. This decrease was due to a lower level of medical
practice transactions in 1998 offset by increased repayments of other
indebtedness and increased purchases of the Company's Common Stock. Repurchased
shares of Common Stock are used primarily to fulfill commitments for delivery
of the Company's Common Stock under medical practice transactions.
At December 31, 1998, the Company had working capital of $87.0 million,
including cash and equivalents of $10.6 million. The Company had $84.6 million
of current liabilities, including $14.7 million of long-term indebtedness
maturing before December 31, 1999. The Company's accounts receivable and
accounts payable have increased significantly
19
<PAGE>
during the past several years with the growth of its business. The Company has
not experienced, however, any significant change in the quality of its accounts
receivable and, as a result, its increasing working capital has resulted in
greater liquidity. The Company currently expects that its principal use of funds
in the near future will be in connection with future transactions with oncology
groups, the purchase of medical equipment, investment in information systems and
the acquisition or lease of real estate for the development of integrated cancer
centers. The Company expects that cash generated from operations and amounts
available under the Credit Facility will be adequate to satisfy the Company's
cash requirements for the next 12 months, without giving effect to the AOR-PRN
merger.
The Company is currently negotiating an amendment and restatement of its
Credit Facility that would be effective upon the closing of the merger with PRN.
It is anticipated that, effective upon consummation of the AOR-PRN merger, the
Credit Facility will provide for borrowings of $200 million to $250 million
(including a sub-facility maturing in 364 days). The Company's $75 million
leasing facility would remain in place. In connection with the negotiation of
the amended and restated Credit Facility, the Company has noted that the credit
market for physician practice management companies has significantly weakened;
fewer lenders are willing to lend to the Company at rates historically available
to it. Although the Company currently believes it will be able to secure the
proposed financing under the amended and restated Credit Facility, there can be
no assurance it will be able to do so on favorable terms. If the Company is
unable to secure additional financing in the future, its ability to pursue its
growth strategy of affiliating with oncology groups and constructing cancer
centers may be adversely impacted.
YEAR 2000 ISSUE
The "Year 2000 problem" describes computer programs that use two rather
than four digits to define the applicable year, and thus cannot distinguish
between the year 1900 and the year 2000. These programs are present in the
Company's computer systems and are incorporated into equipment. The Company's
computer hardware and software, building infrastructure components (e.g., alarm
systems and HVAC systems) and medical equipment (e.g., linear accelerators,
which are used to provide radiation therapy) that are date sensitive may contain
programs with the Year 2000 problem. If uncorrected, the problem could result
in computer system and program failure or equipment malfunctions that could
disrupt business operations.
Project. AOR has divided its Year 2000 Project into six phases:
development, awareness, assessment, remediation, validation and implementation.
In connection with AOR's Year 2000 Project, the Company is assessing information
technology software and hardware, medical equipment, third-party payors and
third-party suppliers. The Company's strategy also includes development of
contingency plans to address potential disruption of operations arising from the
Year 2000 problem.
Information Systems. The Company recognizes that investment in information
systems and state-of-the-art medical equipment is integral to its operations.
The majority of the Company's technology expenditures for 1998 and 1999 relates
to the development and implementation of a clinical information system. This
system provides an interactive electronic format for capturing the spectrum of
patient care and creates an electronic medical record. This system is believed
to be Year 2000 compliant. The costs of the clinical information system are
expected to be capitalized and amortized over the life of the asset.
In 1994, the Company began a project to replace the existing practice
management systems (billing and collection systems) with a common system to
improve efficiency and consistency among its affiliated practices. This
practice management system is beginning to be implemented in the first quarter
of 1999. Any remaining practice management systems not replaced by the new
system during the first half of 1999 are expected to be Year 2000 compliant by
March 1999. The Company will complete the testing of these systems in its Year
2000 test facility by June 1999. Costs to upgrade the practice management
systems that are not converted to the common system would be expensed; however,
such costs are not expected to be material.
In 1996, the Company's management incorporated a business strategy to
accommodate the rapid growth of its operations. One component of this strategy
was the investment in developing an integrated financial system throughout its
network of affiliated physicians. This financial system is believed to be Year
2000 compliant and has been implemented in two locations. The Company intends
to complete the implementation of this financial system throughout its network
of affiliated physicians by mid-1999. The costs incurred to date in developing
such a financial system have been capitalized through the initial implementation
date.
20
<PAGE>
Medical Equipment. The Company has reviewed the Year 2000 readiness of the
linear accelerators and associated equipment used in the affiliated radiation
oncology practices. The suppliers of the medical equipment have certified that,
with minor upgrades, these systems will be Year 2000 compliant. These systems
will be upgraded during the first and second quarters of 1999. The Company is
in the process of evaluating the Year 2000 compliance of other clinical
equipment at this time and expects to complete this process by mid-1999. Any
such costs to upgrade equipment will be expensed.
Third-Party Payors. The Company bills and collects for medical services from
numerous third party payors in operating its business. These third parties
include fiscal intermediaries on behalf of the Medicare program, as well as
insurance companies, HMOs and other private payors. As part of the Company's
Year 2000 strategy, a comprehensive survey has been sent to all significant
payors to assess their timeline for Year 2000 compliance and the impact to the
Company. The Company is in the process of assembling and analyzing these
questionnaires.
Third-Party Suppliers. The Company is currently evaluating third party
vendors of medical supplies and pharmaceuticals in order to determine whether
their services and products will be interrupted or malfunction due to the Year
2000 problem. The Company's pharmaceutical ordering system is a proprietary
system developed by a third party vendor and is utilized under the Company's
purchasing contract with such vendor. This relationship has been identified and
prioritized as the most critical in the vendor evaluation process. The third
party vendor is currently upgrading its pharmaceuticals purchase ordering system
at no cost to the Company. The upgraded software is expected to be certified as
Year 2000 compliant by the vendor and is scheduled for implementation by the
second quarter of 1999.
Risks. The failure to correct a material Year 2000 problem could result in an
interruption in, or failure of, certain normal business activities or
operations. Such failures could materially and adversely affect the Company's
results of operations, liquidity and financial condition. Due to the general
uncertainty inherent in the Year 2000 problem, resulting in part from the
uncertainty of the Year 2000 readiness of third-party payors and third-party
suppliers, the Company is unable to determine at this time whether the
consequences of Year 2000 failures will have a material impact on the Company's
results of operations, liquidity or financial condition. The Company's Year
2000 project is expected to significantly reduce the Company's level of
uncertainty about the Year 2000 problem and, in particular, about the Year 2000
compliance and readiness of its payors and suppliers.
Costs. The Company estimates that total costs to be incurred in the execution
of its Year 2000 Project are approximately $4.1 million, including approximately
$600,000 relating to laboratory and medical equipment upgrades and replacements.
The Company estimates that approximately $2.3 million of the costs will be
capitalized and amortized over the useful life of the assets.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS
In the normal course of business, the financial position of the Company is
routinely subjected to a variety of risks. Among these risks is the market risk
associated with interest rate movements on outstanding debt. The Company
regularly assesses these risks and has established policies and business
practices to protect against the adverse effects of these and other potential
exposures.
The Company's borrowings under the Credit Facility and subordinated notes due
to affiliated physicians contain an element of market risk from changes in
interest rates. The Company manages this risk, in part, through the use of
interest rate swaps, as explained in Note 4 of the Company's Consolidated
Financial Statements. The Company does not enter into interest rate swaps or
hold other derivative financial instruments for speculative purposes.
For purposes of specific risk analysis, the Company uses sensitivity analysis
to determine the impact that market risk exposures may have on the Company. The
financial instruments included in the sensitivity analysis consist of all of the
Company's cash and equivalents, long-term and short-term debt and all derivative
financial instruments.
To perform sensitivity analysis, the Company assesses the risk of loss in fair
values from the impact of hypothetical changes in interest rates on market
sensitive instruments. The market values for interest rate risk is computed
based on the present value of future cash flows as impacted by the changes in
the rates attributable to the market risk being measured. The discount rates
used for the present value computations were selected based on market interest
rates in effect at December 31, 1998. The market values that result from these
computations are compared with the market values of these financial instruments
at December 31, 1998. The differences in this comparison are the hypothetical
gains or losses associated with each type of risk. A one percent increase or
decrease in the levels of interest rates on variable rate debt with all other
variables
21
<PAGE>
held constant would not result in a material change to the Company's results of
operations or financial position or the fair value of its financial instruments.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
Reference is made to the Index to Consolidated Financial Statements, which
appears in page 24 of this report.
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE
None.
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
DIRECTORS OF THE REGISTRANT
The following sets forth certain information concerning each of the
directors of the Company.
<TABLE>
<CAPTION>
Name Age Director Since
----- --- --------------
<S> <C> <C>
R. Dale Ross.................................. 52 December 1992
Russell L. Carson............................. 55 December 1992
James E. Dalton............................... 56 May 1998
Lloyd K. Everson, M.D. ....................... 56 November 1993
Kyle M. Fink, M.D. ........................... 56 December 1992
Stanley A. Marks, M.D. ....................... 51 May 1998
Richard B. Mayor.............................. 65 February 1993
Magaral S. Murali, M.D. ...................... 55 April 1994
Robert A. Ortenzio............................ 42 December 1992
Edward E. Rogoff, M.D. ....................... 56 July 1995
</TABLE>
R. Dale Ross has been a Chairman of the Board of Directors and Chief
Executive Officer of AOR since December 1992. From April 1990 until joining
AOR, Mr. Ross was self-employed. From December 1982 until April 1990, Mr. Ross
was employed by HMSS, Inc., a home infusion therapy company. Mr. Ross founded
HMSS, Inc. and served as its President and Chief Executive Officer and as a
director.
Russell L. Carson has been a director of AOR since December 1992. Since
1978, Mr. Carson has been a general partner of Welsh, Carson, Anderson &
Stowe, an investment partnership. Mr. Carson is a director of Quorum Health
Group, Inc.
James E. Dalton has served on AOR's Board of Directors since May 1998. Mr.
Dalton has served as President, Chief Executive Officer and a director of Quorum
Health Group, Inc. since 1990. Prior to joining Quorum, Mr. Dalton served as
regional vice president with HealthTrust, Inc., as division vice president of
Hospital Corporation of American ("HCA") and as regional vice president with HCA
Management Company. Prior to joining HCA, he held management positions with
American MediCorp, Inc., Humana, Inc. and hospitals in Virginia and West
Virginia. He serves on the board of directors of the Nashville Branch of the
Federal Reserve Bank of Atlanta, AmSouth Bank, Housecall Medical Resources, Inc.
and the Nashville Health Care Council. Mr. Dalton is a Fellow of the American
College of Healthcare Executives and is on the board of directors and past
chairman of the Federation of American Health Systems.
Lloyd K. Everson, M.D. has served on AOR's Board of Directors since November
1993. Dr. Everson received his medical degree from Harvard Medical School and
his oncology training at Memorial Sloan Kettering National Cancer Institute. He
is board certified in medical oncology. Prior to joining the Company, Dr.
Everson served as the Medical Director for the Indiana Regional Cancer Center
and was President of LKE Consulting Services. Dr. Everson has been published
widely in the field of oncology and is a member of numerous professional
associations, including the American Society of Clinical Oncology, Association
of Community Cancer Centers and the American College of Physicians. He also has
served as President of the Association of Community Cancer Centers and as
Associate Chairman for Community Programs for the Eastern Cooperative Oncology
Group.
Kyle M. Fink, M.D. has served on AOR's Board of Directors since December,
1992. Dr. Fink obtained his medical degree from Indiana University and his
oncology training at Memorial Sloan Kettering National Cancer Institute. He is
board certified in medical oncology. Since 1975, Dr. Fink has been a practicing
physician and member of Hematology Oncology Associates, an oncology group in
Denver, Colorado that is affiliated with the Company. Dr. Fink has served on
numerous board and professional societies, and has been a member of the Board
of Directors of Presbyterian St. Luke's Medical Center in Denver, Colorado
since 1991.
Stanley A. Marks, M.D. has been a director of AOR since May 1998. Dr. Marks
obtained his medical degree from the University of Pittsburgh School of
Medicine and additional training at Peter Bent Brigham Hospital, Harvard
Medical School and Sidney Farber Cancer Center. Dr. Marks is a member of
numerous professional societies, including the American Society of Hematology
and the American Society of Clinical Oncology. Dr. Marks is a practicing
physician in Pittsburgh, Pennsylvania with Oncology-Hematology Associates, a
physician group affiliated with AOR since April 1995.
Richard B. Mayor has been a director of AOR since February 1993. Mr. Mayor
was a partner in the Houston law firm of Mayor, Day, Caldwell & Keeton, L.L.P.
from its formation in February 1982 until December 1998. Since January 1999 he
has been Of Counsel to such firm. Mayor, Day, Caldwell & Keeton, L.L.P. serves
as outside legal counsel to AOR.
Magaral S. Murali, M.D. has served on AOR's Board of Directors since April
1994. Dr. Murali obtained his medical degree from Madras Medical College,
Madras, India, and his hematology/oncology training at Long Island
Jewish/Hillside Medical Center and Catholic Medical Center. He is board
certified in hematology and medical oncology. Since 1978, Dr. Murali has been a
practicing physician affiliated with Oncology and Hematology Associates, a
physician group affiliated with the Company in Indianapolis, Indiana.
Robert A. Ortenzio has been a director of AOR since December 1992. Mr.
Ortenzio has been President and Chief Operating Officer of Select Medical
Corporation since February 1997. Prior to that time, Mr. Ortenzio was a co-
founder and president of Continental Medical Systems, Inc., a provider of
comprehensive medical rehabilitation programs and services, and a director of
Horizon/CMS Healthcare Corporation, and served in various capacities at
Continental Medical Systems, Inc. since February 1986. Mr. Ortenzio is
currently a director of Concetra Managed Care, Inc. and Centennial Healthcare
Corp.
Edward E. Rogoff, M.D. has been a director of AOR since July 1995. Dr.
Rogoff obtained his medical degree from the State University of New York,
Downstate Medical School, and his training in radiation oncology from Memorial
Sloan Kettering Cancer Center. He is board certified in radiation oncology.
Since 1978, Dr. Rogoff has been affiliated with Southwest Radiation Oncology,
Ltd., an oncology group in Tucson, Arizona managed by AOR since January 1995.
Dr. Rogoff is a member of numerous professional societies including American
Society of Therapeutic Radiology and Oncology and the American Society of
Clinical Oncology.
Pursuant to General Instruction G (3), certain information concerning the
executive officers of the Company is included in Part I of this Form 10-K under
the caption "Executive Officers."
SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
Under the federal securities laws, the Company's directors, executive
officers and any person holding more than ten percent of the outstanding common
stock are required to report their beneficial ownership of AOR common stock to
the Company and the SEC. Specific due dates for these reports have been
established by regulation, and the Company is required to report any failure to
file by these dates during 1998. The Company believes that all directors,
officers and ten percent holders are current in their filings with respect to
1998. In making these statements, the Company has relied on the written
representations of its directors, officers and ten percent holders and copies of
reports that they have filed with the SEC.
ITEM 11. EXECUTIVE COMPENSATION
The following tables set forth (i) the aggregate amount of remuneration paid
by the Company for the three fiscal years ended December 31, 1998 to the Chief
Executive Officer and the four most highly compensated executive officers other
than the Chief Executive Officer, (ii) the number of shares of the Company's
common stock that are subject to options granted to such individuals during the
last fiscal year and the hypothetical value thereof assuming specified annual
rates of AOR common stock price appreciation, and (iii) the amount realized upon
the exercise of stock options during the last fiscal year and the value at the
end of the last fiscal year of all stock options held by such individuals.
SUMMARY COMPENSATION TABLE
<TABLE>
<CAPTION>
Annual Long Term
Compensation Compensation
---------------- ------------
Securities
Fiscal Underlying
Year Salary Bonus Options
Name and Principal Position ------ ------ ------- ------------
<S> <C> <C> <C> <C>
R. Dale Ross.............................. 1998 $438,900 $ 0 100,000
Chairman of the Board, Chief Executive
Officer 1997 $399,000 $ 0 200,000
and Director 1996 $350,000 $ 0 0
Lloyd K. Everson, M.D..................... 1998 $368,362 $ 0 75,000
President and Director 1997 $334,875 $ 0 175,000
1996 $293,750 $ 0 0
L. Fred Pounds............................ 1998 $302,485 $ 0 50,000
Vice President of Finance, Treasurer and
Chief 1997 $274,986 $ 0 100,000
Financial Officer 1996 $239,119 $ 0 0
David S. Chernow.......................... 1998 $220,000 $ 0 50,000
Chief Development Officer 1997 $200,000 $ 0 100,000
1996 $135,000 $42,800 60,000
R. Allen Pittman.......................... 1998 $166,676 $40,000 50,000
Vice President of Corporate Services 1997 $151,524 $ 0 5,000
1996 $142,947 $43,565 44,000
</TABLE>
OPTION GRANTS DURING YEAR ENDED DECEMBER 31, 1998
<TABLE>
<CAPTION>
Potential Realizable Value
at Assumed Annual Rates of
Stock Price Appreciation
Individual Grants for Option Term
------------------------------------------- ---------------------------
Number of % of Total Exercise
Securities Options Price
Underlying Granted to Per
Options Employees in Share Expiration
Name Granted Fiscal Year (1) Date 5% 10%
- ------------------------ ---------- ------------ -------- ---------- ------------ --------------
<S> <C> <C> <C> <C> <C> <C>
R. Dale Ross............ 100,000 11.0% $14.61 5/14/08 $ 918,820 $ 2,328,460
Lloyd K. Everson, M.D... 75,000 8.3% $14.61 5/14/08 $ 689,115 $ 1,746,345
L. Fred Pounds.......... 50,000 5.5% $14.61 5/14/08 $ 459,410 $ 1,164,230
David S. Chernow........ 50,000 5.5% $14.61 5/14/08 $ 459,410 $ 1,164,230
R. Allen Pittman........ 50,000 5.5% $14.61 5/14/08 $ 459,410 $ 1,164,230
</TABLE>
- --------
(1) The exercise price per share for each option granted in 1998 is the market
value of the Company's common stock as of the date such option was granted,
as determined in accordance with the applicable stock option plan.
1998 OPTION EXERCISES AND DECEMBER 31, 1998 OPTION VALUE TABLE
<TABLE>
<CAPTION>
Number of Securities
Underlying Unexercised Value of Unexercised
Shares Options at Fiscal Year In-the-Money Options at
Acquired End Fiscal Year End(1)
on Value ------------------------- -------------------------
Name Exercise Realized Exercisable Unexercisable Exercisable Unexercisable
---- -------- ---------- ----------- ------------- ----------- -------------
<S> <C> <C> <C> <C> <C> <C>
R. Dale Ross............ 400,000 $5,974,953 1,858,428 260,000 $19,716,423 $ 0
Lloyd K. Everson, M.D... 200,000 $2,475,000 332,864 215,000 $ 2,927,120 $ 0
L. Fred Pounds.......... 115,000 $1,381,575 257,973 233,439 $ 2,640,832 $1,107,528
David S. Chernow........ 35,000 $ 319,212 24,242 174,000 $ 118,269 $ 611,510
R. Allen Pittman........ 20,000 $ 283,300 30,600 88,400 $ 230,849 $ 251,904
</TABLE>
- --------
(1) Based upon a closing price of the Company's common stock on December 31,
1998, as reported by The Nasdaq Stock Market, of $14.56 per share.
401(k) Plan
Effective January 1, 1994, the Company adopted a 401(k) plan covering
substantially all employees who have completed at least 1,000 hours of service.
The Company's 401(k) Plan is administered by the Company and permits covered
employees to contribute up to 15% of their annual compensation up to the maximum
legally allowable contribution per year, as adjusted for inflation, through
salary reduction on a pre-tax basis in accordance with Section 401(k) of the
Code. Company contributions to the Company's 401(k) Plan are permitted, but are
not required. No contributions have been made by the Company to date.
Indemnification of Officers and Directors
The Company's certificate of incorporation provides that no director of the
Company shall be personally liable to the Company or its stockholders for
monetary damages for breach of fiduciary duty as a director, except for
liability (i) for any breach of the director's duty of loyalty to the Company
or its stockholders, (ii) for acts or omissions not in good faith or that
involve intentional misconduct or a knowing violation of law, (iii) in respect
of certain unlawful dividend payments or stock redemptions or repurchases as
provided in Section 174 of the Delaware General Corporation Law or (iv) for any
transaction from which the director derived an improper personal benefit. The
effect of these provisions is to eliminate the rights of the Company and its
stockholders (through stockholders' derivative suits on behalf of the Company)
to recover monetary damages against a director for breach of fiduciary duty as
a director (including breaches resulting from grossly negligent behavior),
except in the situations described above. The SEC has taken the position that
the provision will have no effect on claims arising under federal securities
laws.
The Company's bylaws provide that the Company will indemnify its directors
and officers to the fullest extent permissible under Delaware law. These
indemnification provisions require the Company to indemnify such persons against
certain liabilities and expenses to which they may become subject by reason of
their service as a director or officer of the Company or any of its affiliated
enterprises. The provisions also set forth certain procedures, including the
advancement of expenses, that apply in the event of a claim for indemnification.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following tables set forth information with respect to the beneficial
ownership of the Company's common stock as of April 28, 1999 (or such other date
indicated below) by (i) each owner of more than 5% of such common stock, (ii)
each director of the Company, (iii) certain executive officers of the Company,
including the Chief Executive Officer and the four most highly compensated
officers other than the Chief Executive Officer who were serving as officers at
December 31, 1998, and (iv) all executive officers and directors as a group.
Except as otherwise indicated below, each of the entities and persons named in
the tables has sole voting and investment power with respect to all shares of
common stock beneficially owned. For purposes of these tables, a person or group
of persons is deemed to have "beneficial ownership" of any shares as of a given
date which such person has the right to acquire within 60 days after such date.
For purposes of computing the percentage of outstanding shares held by each
person or group of persons named below on a given date, any security which such
person or persons has the right to acquire within 60 days after such date is
deemed to be outstanding for the purpose of computing the percentage ownership
of such person or persons, but is not deemed to be outstanding for the purpose
of computing the percentage ownership of any other person. Unless otherwise
indicated, the address for each of the individuals or entities named in the
tables below is the principal executive offices of AOR .
<TABLE>
<CAPTION>
Number of
Shares Number of AOR
(including options
options currently
included Percentage exercisable or
in column of Beneficial exercisable
Name 3) Ownership within 60 days
---- ---------- --------------------- --------------
<S> <C> <C> <C>
R. Dale Ross............... 1,878,428 5.3% 1,878,428
Lloyd K. Everson, M.D...... 392,166(1) 1.1 347,864
David S. Chernow........... 60,373 * 58,242
R. Allen Pittman........... 45,600 * 45,600
L. Fred Pounds............. -- * 333,492
Russell L. Carson.......... 1,861,157(2) 5.6 7,000
James E. Dalton, Jr........ 7,000 * 7,000
Kyle M. Fink, M.D.......... 509,258 1.5 7,000
Stanley M. Marks, M.D...... 70,266(3) * 5,000
Richard B. Mayor........... 102,454 * 32,000
Magaral S. Murali, M.D..... 135,684(4) * 7,000
Robert A. Ortenzio......... 53,007(5) * 7,000
Edward E. Rogoff, M.D...... 131,335(6) * 7,600
Welsh, Carson, Anderson &
Stowe..................... 1,452,154(7) 4.3 0
T. Rowe Price Associates,
Inc....................... 2,526,071(8) 7.6% 0
100 E. Pratt Street
Baltimore, Maryland 21202
Brown Investment Advisory &
Trust Company............. 2,255,942(9) 6.7% 0
19 South Street
Baltimore, Maryland 21202
Putnam Investments, Inc.... 2,192,900(10) 6.6% 0
One Post Office Square
Boston, Massachusetts
02109
All executive officers and
directors as a group (15
persons).................. 5,831,823 15.9 2,903,434
</TABLE>
- --------
*Less than one percent.
(1) Includes 38,302 shares owned by the Lloyd K. Everson Profit Sharing Plan.
(2) Includes 1,452,154 shares owned by Welsh, Carson, Anderson & Stowe V, L.P.
Mr. Carson disclaims beneficial ownership of such shares that exceed his
pecuniary interest therein. Includes 4,000 shares held by family trusts.
Mr. Carson disclaims beneficial ownership of such shares.
(3) Does not include 46,530 shares and 116,326 shares of AOR common stock that
Dr. Marks has the right to receive from AOR for no additional consideration
on April 1, 1999 and April 1, 2000, respectively.
(4) Does not include 323,890 shares of AOR common stock Dr. Murali is entitled
to receive on April 1, 1999 for no additional consideration.
(5) Excludes 48,588 shares of AOR common stock with respect to which Mr.
Ortenzio has a remainder interest.
(6) Includes 20,000 shares held by the Miked Profit Sharing Plan, of which Dr.
Rogoff is a trustee and beneficiary. Excludes 218,180 shares of AOR common
stock Dr. Rogoff is entitled to receive on January 31, 2000 for no
additional consideration.
(7) Welsh, Carson, Anderson & Stowe's address is: 1 World Financial Center,
Suite 3601, New York, New York 10281. Includes 1,452,154 shares owned by
Welsh, Carson, Anderson & Stowe V, L.P. Mr. Carson disclaims beneficial
ownership of such shares that exceed his pecuniary interest therein.
(8) Ownership as of December 31, 1998, as indicated on a Schedule 13-G filed
with the Securities and Exchange Commission. The Schedule 13-G discloses
that such person has sole voting power with respect to 492,571 of such
shares and sole dispositive power with respect to all such shares and does
not have shared voting or dispositive power with respect to any such
shares.
(9) Ownership as of December 31, 1998, as indicated on a Schedule 13-G filed
with the Securities and Exchange Commission. Includes 1,717,058 shares of
AOR common stock owned by Brown Advisory Incorporated, a wholly owned
subsidiary of Brown Investment Advisory & Trust Company. The Schedule 13-G
discloses that such persons together have sole voting power with respect to
2,193,242 of such shares, and no voting power with respect to any other
shares.
(10) Ownership as of December 31, 1998, as indicated on a Schedule 13-G filed
with the Securities and Exchange Commission. Includes 1,658,100 shares
beneficially owned by Putnam Investment Management, Inc., and 534,800
shares beneficially owned by The Putnam Advisory Company. The Schedule 13-
G discloses that such persons do not have sole voting or dispositive power
with respect to any such shares, such persons together share dispositive
power with respect to all of such shares and The Putnam Advisory Company
has shared voting power with respect to 426,800 such shares.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
The Company does not believe that any of the transactions described below
were made on terms less favorable to the Company than those that would have been
available from unaffiliated parties and does not anticipate entering into
transactions with affiliated parties in the future on terms less favorable than
those that would be available from unaffiliated parties.
Dr. Fink, a director of the Company, is a practicing physician with
Hematology Oncology Associates ("HOA"), a physician group affiliated with AOR
since November 1992. During 1998, the Company recognized revenue of
approximately $18,920,000 from HOA. In addition, the Company leases office space
from an entity affiliated with Dr. Fink. Payments under this lease were
approximately $534,000 in 1998.
Dr. Marks, a director of the Company, is a practicing physician with
Oncology-Hematology Associates, a physician group affiliated with the Company
since April 1995. During 1998, the Company recognized revenue of approximately
$30,940,000 from Oncology-Hematology Associates.
Dr. Murali, a director of the Company, is a practicing physician with
Oncology and Hematology Associates, Inc., a physician group affiliated with the
Company since April 1994. During fiscal 1998, the Company recognized revenue of
approximately $16,940,000 from Oncology and Hematology Associates, Inc.
Dr. Rogoff, a director of the Company, is a practicing physician with
Southwestern Radiation Oncology, Ltd., a physician group affiliated with AOR
since January 1995. During fiscal 1998, the Company recognized revenue of
$5,851,000 from Southwestern Radiation Oncology Ltd. In addition, AOR leases
office space from an entity affiliated with Dr. Rogoff. Payments under this
lease were approximately $215,000 in 1998.
Richard B. Mayor, a director of the Company, is Of Counsel to Mayor, Day,
Caldwell & Keeton, L.L.P., the Company's principal outside legal counsel.
PART IV
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K
(a) The following documents are files as a part of this report:
1. Financial Statements: See Item 8 of this report
2. Financial Statement Schedules: See Item 8 of this report
3. Exhibit Index
Exhibit
No. Description
------- -----------
2.1 Agreement and Plan of Merger by American Oncology Resources, Inc.,
Diagnostic Acquisition, Inc. and Physician Reliance Network, Inc.
(filed as an Exhibit to the Form 8-K filed with the Securities and
Exchange Commission on December 15, 1998)
3.1 Certificate of Incorporation of the Company, as amended
(incorporated by reference from Form 10-Q for the period ended
June 30, 1997)
22
<PAGE>
3.2 By-Laws of the Company, as amended (incorporated by reference from
Form 10-Q for the period ended June 30, 1997)
4.1 Rights Agreement between the Company and American Stock Transfer &
Trust Company (incorporated by reference from Form 8-A filed June
2, 1997)
10.1 Third Amended and Restated Loan Agreement among the Company and
First Union National Bank, as agent (filed as Exhibit 10.1 to Form
10-K for the year ended December 31, 1997 and incorporated herein
by reference)
10.2 Participation Agreement among AOR Synthetic Real Estate, Inc., the
Company, First Union National Bank and the other parties
identified therein (filed as Exhibit 10.2 to Form 10-K for the
year ended December 31, 1997 and incorporated herein by reference)
10.3 Credit Agreement among the Company, First Security Bank, First
Union National Bank and the other parties identified therein
(filed as Exhibit 10.3 to Form 10-K for the year ended December
31, 1997 and incorporated herein by reference)
10.4 Chief Executive Officer Stock Option Plan and Agreement (filed as
an exhibit to the Registration Statement on Form S-1 (Registration
No. 33-90634) and incorporated herein by reference)
10.5 Everson Stock Option Plan and Agreement (filed as an exhibit to
the Registration Statement on Form S-1 (Registration No. 33-90634)
and incorporated herein by reference)
10.6 Non-Employee Director Stock Option Plan (filed as an exhibit to
the Company's Quarterly Report on Form 10-Q for the quarter ended
June 30, 1996 and incorporated herein by reference)
10.7 Amendment to Non-Employee Director Stock Option Plan (filed as
Exhibit A to the Company's Proxy Statement for its 1998 Annual
Meeting of Stockholders and incorporated herein by reference)
10.8 Key Employee Stock Option Plan, as amended (filed as an exhibit to
the Registration Statement on Form S-8 (Registration No.
333-30057) and incorporated herein by reference)
10.9 Amendment to Key Employee Stock Option Plan (filed as Exhibit B to
the Company's Proxy Statement for its 1998 Annual Meeting of
Stockholders and incorporated herein by reference)
10.10 Affiliate Stock Option Plan (filed as an exhibit to the
Registration Statement on Form S-1 (Registration No. 33-90634) and
incorporated herein by reference)
10.11 Severance Agreement, effective as of November 6, 1998, between the
Company and Larry D. Gray. (previously filed as an exhibit to the
Company's Annual Report on Form 10-K for the year ended
December 31, 1998)
21.1 Subsidiaries of the Registrant (previously filed as an exhibit to
the Company's Annual Report on Form 10-K for the year ended
December 31, 1998)
23.1 Consent of Independent Accountants
27 Financial Data Schedule
(b) Reports on Form 8-K.
On December 15, 1998, the Company filed a Form 8-K with the Securities
and Exchange Commission regarding the execution of an Agreement and Plan of
Merger with Physician Reliance Network, Inc. ("PRN"). Pursuant to the
Agreement and Plan of Merger and subject to the terms and conditions set
forth therein, a wholly owned subsidiary of AOR will merge with and into
PRN, with PRN surviving as a wholly owned subsidiary of AOR. At the
effective time of the merger, each PRN shareholder will receive 0.94 shares
of AOR common stock for each share of PRN common stock owned by such
shareholder.
23
<PAGE>
AMERICAN ONCOLOGY RESOURCES, INC.
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
Consolidated Financial Statements as of December 31, 1998 and 1997 and for each
of the three years ended December 31, 1998:
<TABLE>
<CAPTION>
Page
----
<S> <C>
Report of Independent Accountants................ 25
Consolidated Balance Sheet....................... 26
Consolidated Statement of Operations............. 27
Consolidated Statement of Stockholders' Equity... 28
Consolidated Statement of Cash Flows............. 29
Notes to Consolidated Financial Statements....... 30
</TABLE>
Financial statement schedules have been omitted because they are not applicable
or the required information is shown in the consolidated financial statements or
notes thereto.
24
<PAGE>
REPORT OF INDEPENDENT ACCOUNTANTS
To the Stockholders and Board of Directors of
American Oncology Resources, Inc.
In our opinion, the consolidated financial statements listed in the index on
page 24 present fairly, in all material respects, the financial position of
American Oncology Resources, Inc. and its subsidiaries at December 31, 1998 and
1997, and the results of their operations and their cash flows for each of the
three years in the period ended December 31, 1998, in conformity with generally
accepted accounting principles. These financial statements are the
responsibility of the Company's management; our responsibility is to express an
opinion on these financial statements based on our audits. We conducted our
audits of these statements in accordance with generally accepted auditing
standards, which require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements, assessing the
accounting principles used and significant estimates made by management, and
evaluating the overall financial statement presentation. We believe that our
audits provide a reasonable basis for the opinion expressed above.
/s/ [Signature Appears Here]
PRICEWATERHOUSECOOPERS LLP
Houston, Texas
March 2, 1999
25
<PAGE>
AMERICAN ONCOLOGY RESOURCES, INC.
CONSOLIDATED BALANCE SHEET
(in thousands, except share amounts)
<TABLE>
<CAPTION>
December 31,
--------------------
1998 1997
-------- --------
<S> <C> <C>
ASSETS
Current assets:
Cash and equivalents................................................................. $ 10,618 $ 5,000
Accounts receivable.................................................................. 133,465 92,038
Prepaids and other current assets.................................................... 14,006 10,149
Due from affiliated physician groups................................................. 13,527 7,904
-------- --------
Total current assets.............................................................. 171,616 115,091
Property and equipment:
Land................................................................................. 2,229 2,229
Computers and software............................................................... 21,891 11,617
Equipment, furniture and fixtures.................................................... 30,184 20,578
Buildings and leasehold improvements................................................. 20,962 16,685
-------- --------
75,266 51,109
Less accumulated depreciation and amortization...................................... (21,776) (12,545)
-------- --------
53,490 38,564
Management service agreements, net of accumulated amortization of $27,459 and $15,589... 338,673 326,295
Other assets............................................................................ 4,321 3,943
-------- --------
$568,100 $483,893
======== ========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Short-term notes payable............................................................ $ - $ 14,011
Current maturities of long-term indebtedness........................................ 14,708 8,628
Accounts payable.................................................................... 48,207 38,870
Due to affiliated physician groups.................................................. 1,799 289
Accrued compensation costs.......................................................... 4,381 2,783
Accrued interest payable............................................................ 4,408 2,804
Income taxes payable................................................................ 6,435 8
Other accrued liabilities........................................................... 9,662 3,834
-------- --------
Total current liabilities......................................................... 89,600 71,227
Deferred income taxes.................................................................. 10,973 8,956
Long-term indebtedness................................................................. 173,140 139,716
-------- --------
Total liabilities................................................................. 273,713 219,899
-------- --------
Stockholders' equity:
Preferred stock, $.01 par value, 1,000,000 shares authorized, none issued and
outstanding
Series A Preferred Stock, $.01 par value, 500,000 shares authorized and reserved,
none issued and outstanding
Common Stock, $.01 par value, 80,000,000 shares authorized, 32,749,222 and
29,721,754 shares issued and 32,373,922 and 29,721,754 shares outstanding.......... 328 297
Additional paid-in capital.......................................................... 148,425 138,381
Common stock to be issued, 15,540,928 and 17,937,752 shares......................... 70,643 74,757
Treasury stock 375,300 shares....................................................... (3,696) -
Retained earnings................................................................... 78,687 50,559
-------- --------
Total stockholders' equity........................................................ 294,387 263,994
-------- --------
Commitments and contingencies (Notes 3, 4, 6, and 8)................................... - -
-------- --------
$568,100 $483,893
======== ========
</TABLE>
The accompanying notes are an integral part of this statement.
26
<PAGE>
AMERICAN ONCOLOGY RESOURCES, INC.
CONSOLIDATED STATEMENT OF OPERATIONS
(in thousands, except per share data)
<TABLE>
<CAPTION>
Year Ended December 31,
------------------------------
1998 1997 1996
---- ---- ----
<S> <C> <C> <C>
Revenue................................ $455,952 $321,840 $205,460
-------- -------- --------
Operating expenses:
Pharmaceuticals and supplies......... 207,930 144,890 85,210
Practice compensation and benefits... 86,136 61,296 41,350
Other practice costs................. 51,769 35,090 23,495
General and administrative........... 26,201 21,174 14,095
Depreciation and amortization........ 23,287 14,177 9,343
-------- -------- --------
395,323 276,627 173,493
-------- -------- --------
Income from operations................. 60,629 45,213 31,967
Other income (expense):
Interest income...................... 222 348 1,062
Interest expense..................... (12,096) (8,715) (4,307)
-------- -------- --------
Income before income taxes............. 48,755 36,846 28,722
Income taxes........................... 18,527 13,979 11,072
-------- -------- --------
Net income $ 30,228 $ 22,867 $ 17,650
======== ======== ========
Net income per share - basic........... $ 0.63 $ 0.50 $ 0.40
======== ======== ========
Shares used in per share calculations
- - basic................................ 48,293 45,571 44,228
======== ======== ========
Net income per share - diluted......... $ 0.61 $ 0.48 $ 0.37
======== ======== ========
Shares used in per share calculations
- - diluted.............................. 49,845 48,100 47,549
======== ======== ========
</TABLE>
The accompanying notes are an integral part of this statement.
27
<PAGE>
AMERICAN ONCOLOGY RESOURCES, INC.
CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
(IN THOUSANDS)
<TABLE>
<CAPTION>
Common Stock Additional Common Treasury
------------------------ Paid-In Stock to Stock Retained
Shares Par Value Capital Be Issued Cost Earnings Total
------- -------- ---------- ----------- --------- ---------- ----------
<S> <C> <C> <C> <C> <C> <C> <C>
Balance at December 31, 1995...... 27,477 $275 $133,242 $46,018 $11,645 $191,180
Medical practice transactions
value of 2,313,250 shares
to be issued..................... 15,312 15,312
Purchase of 1,110,500 shares
of Treasury Stock................ $(9,414) (9,414)
Delivery of 112,440 shares of
Common Stock to be issued
from Treasury.................... (555) (105) 884 (224)
Exercise of options to purchase
Common Stock..................... 892 9 1,116 1,125
Tax benefit from exercise of non-
qualified stock options.......... 6,001 6,001
Net income........................ 17,650 17,650
------- ------ -------- ------- ------ ------- --------
Balance at December 31, 1996...... 28,369 284 139,804 61,225 (8,530) 29,071 221,854
Medical practice transactions
value of 3,066,859 shares
to be issued..................... 22,355 22,355
Purchase of 657,000 shares of
Treasury Stock................... (6,418) (6,418)
Delivery of 1,650,064 shares of
Common Stock to be issued
from Treasury.................... (7,981) (5,540) 14,900 (1,379)
Delivery of 941,825 shares from
Issuance of Common Stock......... 942 9 3,274 (3,283)
Exercise of options to purchase
Common Stock..................... 411 4 1,242 48 1,294
Tax benefit from exercise of non-
qualified stock options.......... 2,042 2,042
Net income........................ 22,867 22,867
------- ------ -------- ------- ------ ------- --------
Balance at December 31, 1997...... 29,722 297 138,381 74,757 50,559 263,994
Medical practice transactions
value of 543,787 shares
to be issued..................... 4,541 4,541
Purchase of 1,232,500 shares of
Treasury Stock................... (12,431) (12,431)
Delivery of 857,200 shares of
Common Stock to be issued
from Treasury.................... (4,147) (2,488) 8,735 (2,100)
Delivery of 2,083,411 shares from
Issuance of Common Stock......... 2,083 21 6,146 (6,167)
Exercise of options to purchase
Common Stock..................... 944 10 2,515 2,525
Tax benefit from exercise of non-
qualified stock options.......... 5,530 5,530
Net income........................ 30,228 30,228
------- ------ -------- ------- ------ ------- --------
Balance at December 31, 1998...... 32,749 $328 $148,425 $70,643 $(3,696) $78,687 $294,387
======= ====== ======== ======= ======= ======= ========
</TABLE>
The accompanying notes are an integral part of this statement.
28
<PAGE>
AMERICAN ONCOLOGY RESOURCES, INC.
CONSOLIDATED STATEMENT OF CASH FLOWS
(IN THOUSANDS)
<TABLE>
<CAPTION>
Year Ended December 31,
----------------------------
1998 1997 1996
---- ---- ----
<S> <C> <C> <C>
Cash flows from operating activities:
Net income............................................................... $ 30,228 $ 22,867 $ 17,650
Noncash adjustments:
Depreciation and amortization......................................... 23,287 14,177 9,343
Deferred income taxes................................................. 1,798 5,916 2,130
Imputed interest on medical practice transactions..................... - 248 122
Cash provided (used), net of effects of medical practice transactions,
by changes in:
Accounts receivable................................................... (38,774) (26,392) (24,084)
Prepaids and other current assets..................................... (3,799) (4,342) (2,088)
Other assets.......................................................... 613 - -
Accounts payable...................................................... 7,278 22,064 1,670
Due from/to affiliated physician groups............................... (3,724) (2,636) (2,524)
Income taxes payable.................................................. 11,957 1,409 2,672
Other accrued liabilities............................................. 8,802 71 2,068
-------- -------- --------
Net cash provided by operating activities........................... 37,666 33,382 6,959
Cash flows from investing activities:
Sales of short-term investments.......................................... - - 44,967
Acquisition of property and equipment................................ (22,550) (22,538) (10,030)
Net payments in medical practice transactions............................ (14,473) (33,228) (46,221)
Other.................................................................... 316 1,188 (3,052)
-------- -------- --------
Net cash used by investing activities............................... (36,707) (54,578) (14,336)
Cash flows from financing activities:
Proceeds from Credit Facility............................................ 46,000 142,000 23,000
Repayment of Credit Facility............................................. (8,000) (99,000) -
Repayment of other indebtedness.......................................... (23,435) (14,549) (17,444)
Debt financing costs..................................................... - (560) (1,277)
Proceeds from exercise of stock options.................................. 2,525 1,294 1,125
Purchase of Treasury Stock............................................... (12,431) (6,418) (9,414)
-------- -------- --------
Net cash provided (used) by financing activities.................... 4,659 22,767 (4,010)
-------- -------- --------
Increase (decrease) in cash and equivalents................................ 5,618 1,571 (11,387)
Cash and equivalents:
Beginning of period...................................................... 5,000 3,429 14,816
-------- -------- --------
End of period............................................................ $ 10,618 $ 5,000 $ 3,429
======== ======== ========
Interest paid.............................................................. $ 10,017 $ 7,894 $ 3,735
Taxes paid................................................................. 4,490 6,380 6,567
Noncash transactions:
Tax benefit from exercise of non-qualified stock options................. 5,530 2,042 6,001
Value of Common Stock to be issued in medical practice transactions...... 4,541 22,355 15,312
Delivery of Common Stock to be issued in medical practice
transactions.......................................................... 14,902 18,183 884
Debt issued in medical practice transactions............................. 7,829 37,860 25,295
Debt assumed in medical practice transactions............................ 277 4,554 684
Assets acquired under capital lease...................................... 2,268 - -
</TABLE>
The accompanying notes are an integral part of this statement.
29
<PAGE>
AMERICAN ONCOLOGY RESOURCES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
American Oncology Resources, Inc., a Delaware corporation (Company), is a
cancer management company. The Company provides comprehensive management
services under long-term agreements to oncology practices comprised of 358
physicians in 18 states at December 31, 1998. These practices provide a
comprehensive range of medical services to cancer patients, integrating the
multiple specialties of cancer care, including medical and gynecological
oncology, hematology, radiation oncology, diagnostic radiology and stem cell
transplantation.
Effective December 11, 1998, the Company entered into and the board of
directors approved a definitive agreement to merge with Physician Reliance
Network, Inc. (PRN), which provides management services to over 350 oncologists
in 12 states. Under the terms of the agreement, holders of PRN common stock
will receive a fixed ratio of 0.94 shares of the Company's common stock for each
PRN share held. As a result, stockholders of the Company and PRN will each own
approximately 50% of the combined company on a fully-diluted basis. The
transaction is expected to be accounted for under the pooling of interests
method and treated as a tax-free exchange. Closing of the transaction is
anticipated in the second quarter of 1999, subject to stockholder approval of
both companies, regulatory approval and other customary conditions. After
consummation of the transaction, the Company's financial statements will be
retroactively restated to combine the accounts of the Company and PRN for all
periods presented using their historical basis.
The following is a summary of the Company's significant accounting
policies:
Principles of consolidation
The consolidated financial statements include the accounts of the Company
and its wholly owned subsidiaries. All intercompany transactions and balances
have been eliminated.
On November 20, 1997, the Emerging Issues Task Force issued EITF 97-2
"Application of FASB Statement No. 94 and APB Opinion No. 16 to Physician
Practice Management Entities and Certain Other Entities with Contractual
Management Arrangements." EITF 97-2 requires the evaluation of all management
contracts for purposes of determining the need for consolidating the physician
practice based on certain control characteristics. The Company has determined
that all existing management contracts do not meet EITF 97-2 requirements for
consolidation. As the Company has historically not consolidated its affiliated
physician practices, the adoption of EITF 97-2 has no impact on the Company's
financial statements.
Use of estimates
The preparation of the Company's financial statements in conformity with
generally accepted accounting principles requires management to make estimates
and assumptions that affect the reported amounts of assets, liabilities,
revenues and expenses, as well as disclosures of contingent assets and
liabilities. Because of inherent uncertainties in this process, actual future
results could differ from those expected at the reporting date.
Cash equivalents and investments
The Company considers all highly liquid debt securities with original
maturities of three months or less to be cash equivalents.
30
<PAGE>
Revenue recognition
Substantially all of the Company's revenues represent the contractual fees
earned and realizable under its long-term management services agreements with
affiliated physician groups. Each management agreement provides for payment to
the Company of a management fee, which typically includes all practice costs
(other than amounts retained by physicians), a fixed fee, a percentage fee (in
most states) and, if certain financial and performance criteria are satisfied, a
performance fee. The amount of the fixed fee is related to the size of the
affiliation transaction and, as a result, varies significantly among the
management service agreements. The percentage fee, where permitted by applicable
law, is generally seven percent of the affiliated physician group's net revenue.
Performance fees are paid after payment of all practice expenses, physician
compensation and the other management fees and, where permitted by state law,
are approximately 50% of the residual profitability of the physician group.
Management fees are not subject to adjustment with the exception that the fixed
fee may be adjusted from time to time after the fifth year of the management
agreement to reflect inflationary trends. The management service agreements
permit the affiliated physician group to retain a specified amount (typically
23% of the group's net revenues) for physician salaries, and payment of such
salaries is given priority over payment of the management fee. The affiliated
physician group is also entitled to retain all profits of the practice after
payment of the management fee to the Company. The Company recognizes the
management fees as revenue based upon the contractually-agreed amount of such
fees, after taking into consideration the payment priority of physician
compensation.
Accounts Receivable
The Company purchases the accounts receivable generated by affiliated
physician groups from patient services rendered pursuant to the management
services agreements. The accounts receivable are purchased at their net
collectible value, after adjustment for contractual allowances and allowances
for doubtful accounts. The Company is reimbursed by the affiliated physician
groups for any purchased receivables that are deemed uncollectible following the
Company's purchase. Thus, the Company does not have an allowance for doubtful
accounts. If any purchased accounts receivable are subsequently deemed
uncollectible, then the affiliated physician group responsible for the
receivables would reduce its revenue during the period in which the
uncollectible amount is determined. Because the Company's management fee is
based in part on the affiliated physician group's revenue, the reduction in
revenue caused by the uncollectible accounts receivable would proportionally
reduce the Company's management fee. The impact of such adjustments is typically
not significant.
Property and equipment
Property and equipment is stated at cost. Depreciation of property and
equipment is provided using the straight-line method over the estimated useful
lives of three to ten years for equipment, computers and software, and furniture
and fixtures, of the lesser of ten years or the remaining lease term for
leasehold improvements and of twenty years for buildings.
Management service agreements
Management service agreements consist of the costs of purchasing the rights
to manage oncology groups. Under the initial 40-year terms of the agreements,
the affiliated physician groups have agreed to provide medical services on an
exclusive basis only through facilities managed by the Company. The agreements
are noncancelable except for performance defaults. In the event an affiliated
physician group breaches the agreement, or if the Company terminates with cause,
the physician group is required to purchase all related tangible and intangible
assets, including the unamortized portion of the management service agreement,
at the then net book value. The Company amortized these costs over the 40-year
term of the related management service agreement until July 1, 1998, when the
Company changed its amortization period to 25 years on a prospective basis. The
effect of the change during the current year is an increase of approximately
$2.7 million in amortization expense, resulting in a reduction, applying the
Company's effective tax rate, of diluted earnings per share by $0.03.
Under the management services agreements, the Company is the exclusive
provider of management services to its affiliated physician groups, providing
facilities, management information systems, clinical research services,
personnel management and strategic, financial and administrative services.
Specifically, the Company, among other things, (i) prepares financial statements
and operating and capital expenditure budgets, (ii) facilitates the purchase of
pharmaceuticals and other supplies, (iii) performs clerical, accounting and
computer service functions, (iv) organizes and manages clinical research trials
and (v) assists in expanding the scope of services of the affiliated physician
groups.
Each management services agreement provides for the formation of a policy
board, with equal representation from the Company and the affiliated physician
group. The policy board meets periodically, approves those items having a
significant impact on the affiliated physician group and develops the affiliated
physician group's strategic initiatives. The two most significant items reviewed
and approved by the policy board are the annual budget for the group and the
addition of facilities, services or physicians. Each management services
agreement provides a mechanism to adjust the Company's management fee if a
change in law changes the underlying financial arrangement between the Company
and the affiliated physician group. Each agreement also provides for binding
arbitration to resolve disputes between the Company and the affiliated physician
group.
The carrying value of the management service agreements is reviewed for
impairment when events or changes in circumstances indicate their recorded cost
may not be recoverable. If the review indicates that the undiscounted cash
flows from operations of the related management service agreement over the
remaining amortization period is expected to be less than the recorded amount of
the management service agreement, the Company's carrying value of the management
service agreement will be reduced to its estimated fair value.
Other assets
The costs associated with obtaining long-term financing are capitalized and
amortized over the terms of the related debt agreements.
31
<PAGE>
Income taxes
Deferred tax assets and liabilities are determined based on the temporary
differences between the financial statement carrying amounts and the tax bases
of assets and liabilities using the enacted tax rates in effect in the years in
which the differences are expected to reverse. In estimating future tax
consequences, all expected future events are considered other than enactments of
changes in the tax law or rates.
Fair value of financial instruments
The Company's receivables, payables, prepaids and accrued liabilities are
current and on normal terms and, accordingly, are believed by management to
approximate fair value. Management also believes that subordinated notes issued
to affiliated physicians approximate fair value when current interest rates for
similar debt securities are applied. Management estimates the fair value of its
bank indebtedness approximates its book value.
Earnings per share
The Company computes earnings per share in accordance with the provisions
of Financial Accounting Standards Board (FASB) Statement No. 128, "Earnings Per
Share", which requires the Company to disclose "basic" and "diluted" Earnings
per share (EPS). The computation of basic earnings per share is based on a
weighted average number of Common Stock and Common Stock to be issued shares
outstanding during these periods. The Company includes Common Stock to be
issued in both basic and diluted EPS as there are no foreseeable circumstances
which would relieve the Company of its obligation to issue these shares. The
computation of diluted earnings per share is based on the weighted average
number of Common Stock and Common Stock to be issued shares outstanding during
the periods as well as dilutive potential Common Stock calculated under the
treasury stock method.
The following table summarizes the determination of shares used in per share
calculations (in thousands):
<TABLE>
<CAPTION>
Year Ended December 31,
------------------------
1998 1997 1996
---- ---- ----
<S> <C> <C> <C>
Basic
Outstanding at end of period:
Common Stock.................................................... 32,374 29,722 27,371
Common Stock to be issued....................................... 15,541 17,938 17,463
------ ------ ------
47,915 47,660 44,834
Effect of weighting................................................ 378 (2,089) (606)
------ ------ ------
Shares used in per share calculation............................ 48,293 45,571 44,228
====== ====== ======
Diluted
Outstanding at end of period:
Common Stock.................................................... 32,374 29,722 27,371
Common Stock to be issued....................................... 15,541 17,938 17,463
------ ------ ------
47,915 47,660 44,834
Effect of weighting and assumed share equivalents for grants of
stock options and issuances of stock at less than the weighted-
average share price for the year.................................. 1,930 440 2,715
------ ------ ------
Shares used in per share calculation............................ 49,845 48,100 47,549
====== ====== ======
Anti-dilutive stock options not included above....................... 1,609 713 30
</TABLE>
Operating segments
During 1998, the Company adopted FASB Statement No. 131, "Disclosures About
Segments of an Enterprise and Related Information" which requires reporting of
summarized financial results for the operating segments as well as establishes
standards for related disclosures about products and services, geographic areas
and major customers. The Company evaluates performance based on six different
product lines: medical oncology, radiation oncology, gynecological oncology,
stem cell transplantation, diagnostic radiology, and clinical research. The
Company is developing tracking systems for these product lines. Until the
completion of the tracking systems, it is impractical for the Company to
separate operating results for these product lines. For 1998, 1997 and 1996,
medical oncology was the only product line that exceeded the reporting
thresholds of FAS 131. The Company, therefore has used the aggregation criteria
of FAS 131 and reports as a single segment
32
<PAGE>
was the only product line that exceeded the reporting thresholds of FAS 131. The
Company, therefore, has used the aggregation criteria of FAS 131 and reports a
single segment.
Comprehensive income
During 1998, the Company adopted FASB Statement No. 130, "Comprehensive
Income", which establishes standards for reporting and displaying comprehensive
income and its components. In addition to net income, comprehensive income is
comprised of "other comprehensive income" which includes all charges and credits
to equity that are not the result of transactions with owners of the Company's
Common Stock. The Company's net income and comprehensive income were the same
for each of the years-ended December 31, 1998, 1997 and 1996.
Accounting pronouncements for future adoption
In June 1998, FASB issued Statement No. 133, "Accounting for Derivative
Instruments and Hedging Activities," (FAS 133) which is effective for the
Company's financial statements as of and for the year ending December 31, 2000.
FAS 133 requires that an entity recognize all derivatives as either assets or
liabilities in the statement of financial position and to measure those
instruments at fair value. Management expects to implement FAS 133 for the year
ended December 31, 2000 and does not expect such implementation to have a
material effect on the Company's operations.
NOTE 2- REVENUE
Medical service revenue for services to patients by the physician groups
affiliated with the Company is recorded when services are rendered based on
established or negotiated charges reduced by contractual adjustments and
allowances for doubtful accounts. Differences between estimated contractual
adjustments and final settlements are reported in the period when final
settlements are determined. Medical service revenue of the affiliated physician
groups is reduced by amounts retained by the physician groups under the
Company's management service agreements to arrive at the Company's revenue.
The following presents the amounts included in the determination of the
Company's revenues (in thousands):
<TABLE>
<CAPTION>
Year Ended December 31,
-------------------------------
1998 1997 1996
---- ---- ----
<S> <C> <C> <C>
Medical service revenue........................... $601,997 $424,446 $269,380
Amounts retained by affiliated physician groups... 146,045 102,606 63,920
-------- -------- --------
Revenue........................................... $455,952 $321,840 $205,460
======== ======== ========
</TABLE>
In 1998 and 1997, none of the Company's affiliated physician groups
provided more than 10% of revenues. In 1996, 11% of the Company's revenues were
derived from one affiliated physician group, which was the only group that
provided 10% or more of revenues.
For the years ended December 31, 1998, 1997 and 1996, the affiliated
physician groups derived approximately 34%, 33% and 33%, respectively, of their
medical service revenue from services provided under the Medicare and state
Medicaid programs and 47%, 47% and 45%, respectively from contractual, fee-for-
service arrangements with managed care programs, none of which individually
aggregated more than 10% of medical service revenue. The remaining 19%, 20% and
22%, respectively, was derived from various non-contracted fee-for-service
payors. Capitation revenues were less than 1% of total medical service revenue
in 1998, 1997 and 1996. Changes in the payor reimbursement rates, particularly
Medicare due to its concentration, or affiliated physician groups' payor mix can
materially and adversely affect the Company's revenues.
The Company's accounts receivable are a function of medical service revenue
of the affiliated physician group rather than the Company's revenue.
Receivables from the Medicare and state Medicaid programs are considered to have
minimal credit risk, and no other payor comprised more than 10% of accounts
receivable at December 31, 1998.
33
<PAGE>
NOTE 3 - MEDICAL PRACTICE TRANSACTIONS
The consideration paid for the physician groups to enter into long-term
management service agreements and for the nonmedical assets of the physician
groups, primarily receivables and fixed assets, has been accounted for as asset
purchases. Total consideration includes the assumption by the Company of
specified liabilities, the estimated value of nonforfeitable commitments by the
Company to issue Common Stock at specified future dates for no additional
consideration, short-term and subordinated notes, cash payments and related
transaction costs as follows (in thousands):
<TABLE>
<CAPTION>
Year Ended December 31,
----------------------------
1998 1997 1996
---- ---- ----
<S> <C> <C> <C>
Cash and transaction costs.......... $14,473 $ 33,228 $46,221
Short-term and subordinated notes... 7,829 37,860 25,295
Common Stock to be issued........... 4,541 22,355 15,312
Liabilities assumed................. 2,687 8,252 3,794
------- -------- -------
Total costs......................... $29,530 $101,695 $90,622
======= ======== =======
Number of practice affiliations 11 13 17
</TABLE>
During 1998, the Company affiliated with 11 oncology physician groups on
the effective dates indicated as follows: March 26, Landry & Moss, M.D.'s, P.A.
of Bradenton, Florida, total consideration of $3,645,000 including 61,276 shares
of Common Stock to be issued with a value of $604,000; March 31, Dayton
Oncology/Hematology Consultants, P.A. of Dayton, Ohio, total consideration of
$5,560,000 including 115,758 shares of Common Stock to be issued with a value of
$1,048,000; May 1, Colorado Radiation Oncology, P.C. of Denver, Colorado, total
consideration of $3,321,000 including 111,923 shares of Common Stock to be
issued with a value of $1,095,000; August 15, Spector, Zimbler, & DeLeo, M.D.'s
of Berkshire, Massachusetts, total consideration of $2,539,000 including 41,136
shares of Common Stock to be issued with a value of $436,000; September 1,
Arnold Wax, M.D., LTD of Las Vegas, Nevada, total consideration of $4,426,000
including 88,250 shares of Common Stock to be issued with a value of $587,000;
and in July through December of 1998, six smaller transactions with physician
groups in Tucson, Arizona; Oklahoma City, Oklahoma; Kansas City, Missouri;
Dunedin, Florida; Norfolk, Virginia; and Denver, Colorado; for total
consideration of $10,039,000 including 154,308 shares of Common Stock to be
issued with a value of $771,000.
During 1997, the Company affiliated with 13 oncology physician groups on
the effective dates indicated as follows: January 10, Williamsburg Hematology
and Oncology of Virginia, total consideration of $4,566,000 including 94,452
shares of Common Stock to be issued with a value of $588,000; March 14, Virginia
Oncology Associates, P.C., of Norfolk, Virginia, total consideration of
$21,085,000 including 514,124 shares of Common Stock to be issued with a value
of $3,239,000; April 1, Central Indiana Radiation Oncology, P.S.C. of Indiana,
total consideration of $4,622,000 including 253,385 shares of Common Stock to
be issued with a value of $1,393,000; March 24, Texas Radiation Oncology Group,
L.L.P. of Austin, Texas, total consideration of $12,065,000 including 342,632
shares of Common Stock to be issued with a value of $1,754,000; November 1,
Hematology Associates of South Texas, P.A., total consideration of $6,082,000
including 155,396 shares of Common Stock to be issued with a value of
$1,366,000; November 1, Clinical Hematology Oncology Associates, P.C. of
Arizona, total consideration of $9,855,000 including 397,947 shares of Common
Stock to be issued with a value of $3,767,000; November 17, Florida Community
Cancer Centers, P.A. of Tampa, Florida, total consideration of $34,846,000
including 1,117,074 shares of Common Stock to be issued with a value of
$8,964,000; and in January through September of 1997, six smaller transactions
with physician groups in Tulsa, Oklahoma; Las Vegas, Nevada; Portland, Oregon;
Fairfax, Virginia; Vancouver, Washington; and Franklin, Pennsylvania; for total
consideration of $8,574,000 which includes 191,849 shares of Common Stock to be
issued with a value of $1,284,000.
During 1996, the Company affiliated with 17 oncology physician groups on
the effective dates indicated as follows: March 1, Cancer Center of Kansas, P.A.
of Wichita, Kansas, total consideration of $12,547,000 including 163,676 shares
of Common Stock to be issued with a value of $1,926,000; March 1, Coram
Physician Services of Fairfax, Virginia, total consideration of $15,518,000
including 116,298 shares of Common Stock to be issued with a value of
$1,375,000; May 1, San Antonio Tumor and Blood Clinic, P.A. and Drs. Cohen,
Gordon and Lopez, P.A. of San Antonio, Texas, total consideration of $12,479,000
including 210,048 shares of Common Stock to be issued with a value of
$1,980,000; September 1, Central Texas Diagnostic Center, P.A. of Austin, Texas,
total consideration of $18,836,000 including 770,589 shares of Common Stock to
be issued with a value of $4,157,000; November 1, Hematology-Oncology
Associates, P.A. of Jacksonville, Florida, total consideration of $8,012,000
including 258,992 shares of Common Stock to be issued with a value of
$1,113,000; and in January through November of 1996, twelve smaller transactions
with physician groups in Durham, North Carolina; Denver, Colorado; Portland,
Oregon; Tucson, Arizona; San Antonio, Texas; Independence, Missouri; Flagstaff,
Arizona; and Orange Park, St. Augustine and Ocala, Florida; for total
consideration of $23,203,000 which includes 793,647 shares of Common Stock to be
issued with a value of $4,761,000.
In connection with three medical practice transactions occurring in 1997,
the Company issued subordinated promissory notes contingently obligating the
Company to pay up to $1.3 million. Payment under the promissory notes is
contingent on AOR receiving a defined level of management fees during the first
two years following the applicable medical practice transaction which
substantially exceeds the level of management fees expected by AOR during its
negotiations with the practice. Once the payment is fixed, the subordinated
promissory notes are paid in five annual installments, commencing on the third
anniversary of the medical practice transaction. As of December 31, 1998, the
Company has recorded $334,000 of the $1.3 million. (See Note 4--"Subordinated
Notes" herein.) The remainder of such liability, if any, will be recorded in the
period in which the outcome of the contingency becomes probable. Any payment
made will be allocated to the affiliated long-term management services agreement
and will be amortized over the remaining life of that asset.
NOTE 4 - INDEBTEDNESS
Short-term notes payable
Short-term notes payable bear interest at 7% and have original maturities
of less than one year. The notes are payable to physicians with whom the
Company entered into long-term management service agreements and relate to
medical practice transactions. Short-term notes payable amounted to
$14,011,000 at December 31, 1997. These notes were paid in 1998.
Long-term indebtedness
The Company's long-term indebtedness consists of the following (in
thousands):
<TABLE>
<CAPTION>
December 31,
-------------------
1998 1997
---- ----
<S> <C> <C>
Subordinated notes.................... $ 80,611 $ 80,710
Credit Facility....................... 104,000 66,000
Capital lease obligations and other... 3,237 1,634
-------- --------
187,848 148,344
Less - current maturities............. 14,708 8,628
-------- --------
$173,140 $139,716
======== ========
</TABLE>
Subordinated notes
The subordinated notes are issued in substantially the same form in
different series and are payable to the physicians with whom the Company entered
into management service agreements. Substantially all of the notes outstanding
at December 31, 1998 and 1997 bear interest at 7%, are due in installments
through 2005 and are subordinated to senior bank and certain other debt. If the
Company fails to make payments under any of the notes, the respective physician
group can terminate the related management service agreement for cause.
34
<PAGE>
Credit Facility
The Company has a loan agreement and revolving credit/term facility (Credit
Facility) with First Union National Bank (First Union) individually and as Agent
for twelve additional lenders (Lenders), which was amended as of December 29,
1997 to improve certain terms and covenants. Under the terms of the agreement,
the amount available for borrowing is $150 million through October 31, 2002.
Proceeds of loans may be used to finance medical practice transactions, provide
working capital or for other general corporate uses. At December 31, 1998, the
Company had an outstanding balance of $104 million under the Credit Facility.
The Company has classified this facility as long-term due to its ability and
intent to maintain the borrowings past 1999.
Borrowings under the Credit Facility are secured by capital stock of the
Company's subsidiaries and all material contracts, including management service
agreements. At the Company's option, funds may be borrowed at the Base interest
rate or the London Interbank Offered Rate (LIBOR) up to LIBOR plus an amount
determined under a defined formula. The Base rate is selected by First Union
and is defined as its prime rate or Federal Funds Rate plus 1/2%. Interest on
amounts outstanding under Base rate loans is due quarterly while interest on
LIBOR related loans is due at the end of each applicable interest period or
quarterly, if earlier. As of December 31, 1998, the weighted average interest
rate on all outstanding draws was 5.8%.
The Company is subject to restrictive covenants under the Credit Facility,
including the maintenance of certain financial ratios. The agreement also
limits certain activities such as incurrence of additional indebtedness, sales
of assets, investments, capital expenditures, mergers and consolidations and the
payment of dividends. Under certain circumstances, additional medical practice
transactions may require First Union and the Lenders' consent. The proposed
merger with PRN (Note 1) requires consent of the Lenders under the Credit
Facility. The Company is actively negotiating with potential lenders to arrange
for a new expanded Credit Facility and believes that such negotiations will
provide for a five year agreement with terms equivalent to current market
conditions.
Derivatives
As of August 31, 1998, the Company entered into an interest rate swap
agreement with a financial institution to reduce the impact of changes in
interest rates on borrowings under the Credit Facility. The agreement
effectively fixed the interest rate on variable rate debt at a rate of 5.93% per
annum for notional principal amount of $80.0 million through August 30, 1999.
The notional amount of the swap agreement is used to measure the principal
amount upon which fixed rate interest is to be paid or received and does not
represent the amount of exposure to credit loss. The Company is exposed to
credit losses from the counterparty's nonperformance but does not anticipate any
losses because the agreement is with a major financial institution. At December
31, 1998, the fair market value of the interest rate swap was immaterial. The
use of this swap agreement had an insignificant impact on interest expense for
the year ended December 31, 1998.
Capital lease obligations and other
Leases for medical and office equipment are capitalized using effective
interest rates between 6.5% and 11.5%. At December 31, 1998 and 1997, the gross
amount of assets recorded under the capital leases was $5.5 million and $3.2
million and the related accumulated amortization was $2.3 million and $1.9
million, respectively. Amortization expense is included with depreciation in
the accompanying consolidated statement of operations. Total future capital
lease payments are $2.9 million. Other indebtedness consists principally of
installment notes and bank debt, with varying interest rates, assumed in medical
practice transactions.
Maturities
Future principle maturities of long-term indebtedness, including capital
lease obligations, is $14,708,000 in 1999, $16,399,000 in 2000, $17,722,000 in
2001, $120,520,000 in 2002, $10,578,000 in 2003 and $7,921,000 thereafter.
35
<PAGE>
NOTE 5 - INCOME TAXES
The Company's income tax provision consists of the following (in
thousands):
<TABLE>
<CAPTION>
Year Ended December 31,
---------------------------
1998 1997 1996
------- -------- -------
<S> <C> <C> <C>
Federal:
Current................. $15,782 $8,137 $7,787
Deferred................ 1,656 4,592 1,914
State:
Current................. 947 896 1,155
Deferred................ 142 354 216
------- ------- -------
$18,527 $13,979 $11,072
======= ======= =======
</TABLE>
The difference between the effective income tax rate and the amount which
would be determined by applying the statutory U.S. income tax rate before income
taxes is as follows:
<TABLE>
<CAPTION>
Year Ended December 31,
-----------------------
1998 1997 1996
----- ----- -----
<S> <C> <C> <C>
Provision for income taxes at U.S. statutory rates... 35.0% 35.0% 35.0%
State income taxes, net of federal benefit........... 3.0 3.0 3.5
---- ---- ----
38.0% 38.0% 38.5%
==== ==== ====
</TABLE>
Deferred income taxes are comprised of the following (in thousands):
<TABLE>
<CAPTION>
December 31,
-----------------
1998 1997
------- ------
<S> <C> <C>
Deferred tax assets:
Deferred rent................... $ - $ 101
Accrued expenses................ 182 24
Other........................... 386 175
------- ------
$ 568 $ 300
======= ======
Deferred tax liabilities:
Management service agreements... $ 9,679 $7,909
Depreciation.................... 1,799 457
Prepaid expenses................ 63 890
------- ------
$11,541 $9,256
======= ======
</TABLE>
At December 31, 1998, income taxes payable includes a tax liability of
approximately $5 million. The liability has been established related to the
Company's tax position and the possible disallowance of certain deductions taken
in connection with the Company's management services agreements. The impact of
disallowance would be immaterial to the Company's financial condition and
results of operations.
NOTE 6 - STOCKHOLDERS' EQUITY
Effective May 16, 1997, the Board of Directors of the Company adopted a
shareholders rights plan and in connection therewith, declared a dividend of one
Series A Preferred Share Purchase Right for each outstanding share of Common
Stock. For a more detailed description of the shareholders rights plan, refer
to the Company's Form 8-A filed with the Securities and Exchange Commission on
June 2, 1997.
Effective May 8, 1997, the Company's stockholders approved an increase in
the number of shares of Common Stock authorized to be issued to 80,000,000
shares.
On August 13, 1996, the Board of Directors of the Company authorized the
purchase of up to 3,000,000 shares of the Company's Common Stock in public or
private transactions. In 1998, 1997, and 1996, the Company purchased 1,232,500;
657,000; and 1,110,500 shares at aggregate costs of $12.4 million, $6.4 million
and $9.4 million, respectively. Shares
36
<PAGE>
repurchased are used to satisfy commitments for the delivery of the Company's
Common Stock from medical practice transactions.
On May 16, 1996, the Board of Directors of the Company declared a two-for-
one stock split of the Company's Common Stock which was paid on June 10, 1996 to
stockholders of record on May 31, 1996. All references herein to the number of
shares and per share amounts have been adjusted to reflect the effect of the
split.
As part of entering into long-term management services agreements with
physician practices as described in Note 3, the Company has made nonforfeitable
commitments to issue shares of Common Stock at specified future dates for no
further consideration. Holders of the rights to receive such shares have no
dispositive, voting or cash dividend rights with respect to such shares until
the shares have been delivered. Common Stock to be issued is shown as a separate
component in stockholders' equity. The amounts, upon issuance of the shares, are
reclassified to other equity accounts as appropriate.
The shares of Common Stock to be issued at specified future dates were
valued at the transaction date at a discount from the quoted market price of a
delivered share after considering all relevant factors, including normal
discounts for marketability due to the time delay in delivery of the shares. The
discount for shares of Common Stock to be issued at specified future dates is
10% for shares to be delivered prior to the fifth anniversary of the transaction
and is 20% for shares to be delivered thereafter. The Common Stock in the
transactions is to be delivered under the terms of the respective agreements
for periods up to seven years after the initial transaction date. The recorded
value represents management's best estimate of the fair value of the shares of
Common Stock to be delivered in the future as of the transaction date.
For transactions completed through December 31, 1998, the scheduled
issuance of the shares of Common Stock that the Company is committed to deliver
over the passage of time are 6,087,796 in 1999, 4,641,523 in 2000, 1,822,306 in
2001, 2,078,837 in 2002, 703,477 in 2003 and 206,989 thereafter.
NOTE 7 - STOCK OPTIONS
The Company's 1993 Key Employee Stock Option Plan, as amended, provides
that employees may be granted options to purchase Common Stock. Total shares
available for grant are limited to 10% of the outstanding common shares plus
the shares to be issued to physician groups at specified future dates.
Individual option vesting and related terms are determined by the Compensation
Committee of the Board of Directors. However, the stock option plan provides
that the options granted may be incentive options at an exercise price no less
than fair value at the grant date or 85% of fair value in the case of
nonqualified options. Option terms may not exceed ten years. Individual option
grants vest ratably over time, generally five years. Effective November 7,
1996, the Board of Directors exchanged 626,100 options with exercise prices of
$18.10 to $24.18 for new options with an exercise price of $8.79, which
approximated fair value on the date of exchange.
Under the terms of the Company's Chief Executive Officer Stock Option Plan
and Agreement and the Everson Stock Option Plan and Agreement, two executives
were granted 3,693,798 non-qualified options to purchase Common Stock with an
exercise price effectively equal to the fair market value at the date of grant.
The options vested on the date of the Company's initial public offering and
expire between 2000 and 2003. The Company's ability to grant further options
under these plans ceased on the date of the Company's initial public stock
offering. At December 31, 1998, 1,818,428 Common Stock options with a weighted-
average exercise price of $3.72 per share were outstanding and exercisable under
the terms of these plans.
The Company's 1993 Non-Employee Director Stock Option Plan provides that up
to 200,400 options to purchase Common Stock can be granted. The options vest in
6 months or ratably over 4 years, have a term of 10 years and exercise prices
effectively equal to the fair market value at the date of grant. As of December
31, 1998, 79,000 options were outstanding, all of which were vested and
exercisable.
The Company's 1993 Affiliate Stock Option Plan, as amended, provides that
options to purchase up to 1,000,000 shares of Common Stock can be granted.
Options under the plan have a term of 10 years. All individual option grants
vest ratably over the vesting periods of 3 to 5 years. Effective November 7,
1996, the Board of Directors exchanged 61,500 options with exercise prices of
$18.10 to $24.18 for new options with an exercise price of $8.79 which
approximated fair value on the date of grant. Of the outstanding options to
purchase shares of Common Stock granted under this plan, 773,500 were granted to
physician employees of the affiliated physician groups and 46,200 were granted
to other employees of the affiliated physician groups. In 1998 and 1997, the
fair value of the options granted to non-employees was $8.48 and 8.21 per
share, respectively. Compensation expense will be recognized over the
respective vesting periods. Expense of $606,000 and $270,000 was recognized in
1998 and 1997, respectively.
37
<PAGE>
All of the Company's Common Stock options vest automatically upon a change
in control of the Company, as defined in such stock option plans.
The following summarizes the activity for all option plans:
<TABLE>
<CAPTION>
Shares Weighted
Represented Average
by Options Exercise Price
----------- --------------
<S> <C> <C>
Balance, December 31, 1995.................. 5,786,000 $ 5.14
Granted..................................... 1,080,000 13.53
Exercised................................... (893,000) 1.70
Canceled.................................... (1,154,000) 19.09
----------
Balance, December 31, 1996.................. 4,819,000 4.30
Granted..................................... 1,440,000 12.73
Exercised................................... (415,000) 3.14
Canceled.................................... (135,000) 10.68
---------
Balance, December 31, 1997.................. 5,709,000 6.36
Granted..................................... 1,484,000 14.24
Exercised................................... (944,000) 2.87
Canceled.................................... (257,000) 11.25
---------
Balance, December 31, 1998.................. 5,992,000 $8.66
=========
</TABLE>
The following table summarizes information about the Company's stock options
outstanding at December 31, 1998:
<TABLE>
<CAPTION>
Options Outstanding Options Exercisable
---------------------------------------------------- ----------------------------
Number Weighted-Average Weighted Number Weighted
Range of Outstanding Remaining Average Exercisable Average
Exercise Price at 12/31/98 Contractual Life Exercise Price at 12/31/98 Exercise Price
- ----------------- ---------------- ---------------- -------------- ----------- --------------
<S> <C> <C> <C> <C> <C>
$ 1 to 3 1,129,000 2.8 $ 2.65 1,089,000 $ 2.65
4 to 9 2,404,000 5.0 5.85 1,718,000 5.09
10 to 14 1,466,000 9.2 13.01 56,000 10.60
15 to 24 993,000 8.8 15.87 148,000 16.49
--------- ---------
1 to 24 5,992,000 6.3 8.66 3,011,000 4.87
========= =========
</TABLE>
The Company has adopted the disclosure-only provisions of Statement of
Financial Accounting Standards No. 123, "Accounting for Stock-Based
Compensation". Accordingly, no compensation cost has been recognized for fixed
options granted to Company employees. For purposes of pro forma disclosures,
the estimated fair value of the options is amortized to expense over the
options' vesting period. The Company's pro forma information for 1998, 1997 and
1996 are as follows and includes compensation expense of $606,000, $270,000 and
$106,000, respectively (in thousands, except per share amounts):
38
<PAGE>
<TABLE>
<CAPTION>
Year Ended December 31,
-------------------------------------
1998 1997 1996
---------- ----------- ----------
(unaudited)
<S> <C> <C> <C>
Pro forma net income...................... $26,033 $21,102 $16,656
Pro forma net income per share - basic.... $ 0.54 $ 0.46 $ 0.38
Pro forma net income per share - diluted.. $ 0.52 $ 0.44 $ 0.35
</TABLE>
Options granted in 1998, 1997 and 1996 had weighted-average fair values of
$8.46, $9.11 and $6.04 per share, respectively. The fair value of each Common
Stock option grant is estimated on the date of grant using the Black-Scholes
option-pricing model with the following weighted-average assumptions used for
grants from all plans in 1998, 1997 and 1996:
<TABLE>
<CAPTION>
1998 1997 1996
----- ----- -----
<S> <C> <C> <C>
Expected life (years)............ 5 5 5
Risk-free interest rate.......... 4.9% 5.2% 5.1%
Expected volatility (post IPO)... 76% 81% 87%
Expected dividend yield.......... 0% 0% 0%
</TABLE>
NOTE 8 - COMMITMENTS AND CONTINGENCIES
In December 1997, the Company entered into a $75 million master operating
lease related to integrated cancer centers. Under the agreement, the lessor
purchases and has title to the properties, pays for the construction costs and
thereafter leases the facilities under operating leases to the Company. The
initial term of the lease is for five years and can be renewed in one year
increments if approved by the lessor. The Company provides the lessor with
substantial residual value guarantees at the end of each facility lease and has
purchase options at original cost on each property. Advances under the master
lease agreement at December 31, 1998 were $32.3 million.
The Company leases office space, integrated cancer centers and certain
equipment under noncancelable operating lease agreements. Total future minimum
lease payments, including escalation provisions and leases with entities
affiliated with physician groups, are $15,184,000 in 1999, $13,243,000 in 2000,
$12,001,000 in 2001, $9,773,000 in 2002, $9,031,000 in 2003, and $16,842,000
thereafter. Rental expense under noncancelable operating leases was $16,641,000
in 1998, $12,274,000 in 1997 and $8,565,000 in 1996.
The Company and its affiliated physician groups maintain insurance with
respect to medical malpractice risks on a claims-made basis in amounts believed
to be customary and adequate. Management is not aware of any outstanding claims
or unasserted claims probable of assertion against it or its affiliated
physician groups which would have a material impact on the Company's financial
position or results of operations.
NOTE 9 - RELATED PARTIES
The Company receives a contractual management fee for providing management
services to its affiliated physician groups. The Company also advances to its
affiliated physician groups amounts needed for the purchase of pharmaceuticals
and medical supplies necessary in the treatment of cancer. The advances are
reflected on the Company's balance sheet as due from/to affiliated physician
groups and are reimbursed to the Company as part of the management fee payable
under in its management service agreements with its affiliated physician groups.
The Company leases a portion of its medical office space and equipment, at
rates which the Company believes approximate fair market value based upon an
analysis of comparable office space in the geographic areas from entities
affiliated with certain of the stockholders of physician groups affiliated with
the Company. Payments under these leases were $3.7 million in 1998, $2.6
million in 1997, and $2.3 million in 1996 and total future commitments are $16.7
million.
The subordinated notes are payable to the persons or entities which are
also stockholders or holders of rights to receive Common Stock at specified
future dates. Total interest expense to these parties was $5.8 million in 1998,
$5.2 million in 1997, and $3.9 million in 1996.
39
<PAGE>
A director and a stockholder is of counsel and previously was a partner of
a law firm utilized by the Company. The Company incurred $558,000, $584,000,
and $651,000 for legal services provided by the firm in 1998, 1997 and 1996,
respectively.
Four of the Company's directors are practicing physicians with physician
groups affiliated with the Company. In 1998, the physician groups in which
these directors participate generated total medical service revenues of
$94,467,000 of which $21,620,000 was retained by the groups and $72,847,000 was
included in the Company's revenue. In 1997 and 1996, three of the Company's
directors were practicing physicians with physician groups affiliated with the
Company. In 1997, the three physician groups generated total medical service
revenues of $40,378,000 of which $8,484,000 was retained by the groups and
$31,894,000 was included in the Company's revenue. In 1996, the three physician
groups generated total medical service revenues of $37,725,000 of which
$8,218,000 was retained by the groups and $29,507,000 was included in the
Company's revenue.
NOTE 10 - QUARTERLY FINANCIAL DATA
The following table presents the Company's unaudited quarterly information
(in thousands, except per share amounts):
<TABLE>
<CAPTION>
1998 Quarter Ended 1997 Quarter Ended
----------------------------------------- -------------------------------------
Dec 31 Sep 30 Jun 30 Mar 31 Dec 31 Sep 30 Jun 30 Mar 31
------ ------ ------ ------ ------ ------ ------ ------
<S> <C> <C> <C> <C> <C> <C> <C> <C>
Revenue.................. $125,126 $118,263 $111,614 $100,949 $89,626 $82,293 $79,525 $70,396
Income from operations... 15,962 14,964 15,662 14,041 12,468 11,513 11,343 9,889
Net income............... 8,017 7,448 7,892 6,871 6,166 5,910 5,719 5,072
Net income per share
(Basic)................. 0.18 0.15 0.16 0.14 0.13 0.13 0.13 0.11
Net income per share
(Diluted)............... 0.16 0.15 0.16 0.14 0.13 0.12 0.12 0.11
</TABLE>
40
<PAGE>
SIGNATURES
PURSUANT TO THE REQUIREMENTS OF SECTION 13 OF THE SECURITIES EXCHANGE ACT
OF 1934, THE REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON ITS BEHALF
BY THE UNDERSIGNED, THEREUNTO DULY AUTHORIZED, THIS 7TH DAY OF MAY, 1999.
AMERICAN ONCOLOGY RESOURCES, INC.
By: /s/ L. Fred Pounds
---------------------------------------
L. Fred Pounds
Vice President of Finance,
Chief Financial Officer and Treasurer
41
<PAGE>
EXHIBIT 23.1
CONSENT OF INDEPENDENT ACCOUNTANTS
We hereby consent to the incorporation by reference in the Registration
Statements on Form S-8 (No.'s 333-778, 333-780, 333-782, 333-784, 333-786 and
333-30057) of American Oncology Resources, Inc. of our report dated March 2,
1999 appearing on page 25 of this Form 10-K/A.
PRICEWATERHOUSECOOPERS LLP
Houston, Texas
May 7, 1999
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 12-MOS
<FISCAL-YEAR-END> DEC-31-1998
<PERIOD-START> JAN-01-1998
<PERIOD-END> DEC-31-1998
<CASH> 10,618
<SECURITIES> 0
<RECEIVABLES> 133,465
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 171,616
<PP&E> 75,266
<DEPRECIATION> (21,776)
<TOTAL-ASSETS> 568,100
<CURRENT-LIABILITIES> 89,600
<BONDS> 173,140
0
0
<COMMON> 328
<OTHER-SE> 294,387
<TOTAL-LIABILITY-AND-EQUITY> 568,100
<SALES> 0
<TOTAL-REVENUES> 455,952
<CGS> 0
<TOTAL-COSTS> 395,323
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 12,096
<INCOME-PRETAX> 48,755
<INCOME-TAX> 18,527
<INCOME-CONTINUING> 30,228
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 30,228
<EPS-PRIMARY> .63
<EPS-DILUTED> .61
</TABLE>
